Guidelines

Muscle-invasive and Metastatic Bladder Cancer

9. REFERENCES

1.Masson-Lecomte, A., et al. EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma. Edn. presented at the 39th EAU Annual Congress Paris 2024, 2024.

https://uroweb.org/guideline/upper-urinary-tract-urothelial-cell-carcinoma/

2.Gontero, P., et al. EAU Guidelines on Non-muscle-invasive bladder cancer (Ta, T1 and CIS). Edn. presented at the 38th EAU Annual Congress Paris 2024, 2024.

https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/

3.Neuzillet, Y., et al. EAU Guidelines on Primary Urethral Carcinoma. Edn. presented at the 38th EAU Annual Congress Paris 2024, 2024.

https://uroweb.org/guideline/primary-urethral-carcinoma/

4.Alfred Witjes, J., et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol, 2024. 85: 17.

https://www.ncbi.nlm.nih.gov/pubmed/37858453

5.Phillips, B., et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009.

https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009

6.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.

https://www.ncbi.nlm.nih.gov/pubmed/18467413

7.International Agency for Research on Cancer. Estimated number of new cases in 2020, worldwide, both sexes, all ages. Access date December 2022.

https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1

8.Burger, M., et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol, 2013. 63: 234.

https://www.ncbi.nlm.nih.gov/pubmed/22877502

9.Bosetti, C., et al. Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol, 2011. 60: 1.

https://www.ncbi.nlm.nih.gov/pubmed/21497988

10.Teoh, J.Y., et al. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. Eur Urol, 2020. 78: 893.

https://www.ncbi.nlm.nih.gov/pubmed/32972792

11.Chavan, S., et al. International variations in bladder cancer incidence and mortality. Eur Urol, 2014. 66: 59.

https://www.ncbi.nlm.nih.gov/pubmed/24451595

12.Comperat, E., et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch, 2015. 466: 589.

https://www.ncbi.nlm.nih.gov/pubmed/25697540

13.Freedman, N.D., et al. Association between smoking and risk of bladder cancer among men and women. JAMA, 2011. 306: 737.

https://www.ncbi.nlm.nih.gov/pubmed/21846855

14.van Osch, F.H., et al. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol, 2016. 45: 857.

https://www.ncbi.nlm.nih.gov/pubmed/27097748

15.Humans, I.W.G.o.t.E.o.C.R.t. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum, 2004. 83: 1.

https://www.ncbi.nlm.nih.gov/pubmed/15285078

16.Brennan, P., et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer, 2000. 86: 289.

https://www.ncbi.nlm.nih.gov/pubmed/10738259

17.Gandini, S., et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer, 2008. 122: 155.

https://www.ncbi.nlm.nih.gov/pubmed/17893872

18.Al Hussein Al Awamlh, B., et al. Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study. J Urol, 2019. 202: 1248.

https://www.ncbi.nlm.nih.gov/pubmed/31290707

19.Caini, S., et al. Prognostic Impact of Post-Diagnosis Smoking Cessation among Bladder Cancer Patients: A Systematic Literature Review and Meta-Analysis. Cancers (Basel), 2022. 14: 4022.

https://www.ncbi.nlm.nih.gov/pubmed/36011016

20.Zhang, Y., et al. Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study. BMJ, 2020. 370: m2942.

https://www.ncbi.nlm.nih.gov/pubmed/32878860

21.Pashos, C.L., et al. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract, 2002. 10: 311.

https://www.ncbi.nlm.nih.gov/pubmed/12406054

22.Chrouser, K., et al. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol, 2005. 174: 107.

https://www.ncbi.nlm.nih.gov/pubmed/15947588

23.Harling, M., et al. Bladder cancer among hairdressers: a meta-analysis. Occup Environ Med, 2010. 67: 351.

https://www.ncbi.nlm.nih.gov/pubmed/20447989

24.Weistenhofer, W., et al. N-acetyltransferase-2 and medical history in bladder cancer cases with a suspected occupational disease (BK 1301) in Germany. J Toxicol Environ Health A, 2008. 71: 906.

https://www.ncbi.nlm.nih.gov/pubmed/18569594

25.Rushton, L., et al. Occupation and cancer in Britain. Br J Cancer, 2010. 102: 1428.

https://www.ncbi.nlm.nih.gov/pubmed/20424618

26.Nieder, A.M., et al. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol, 2008. 180: 2005.

https://www.ncbi.nlm.nih.gov/pubmed/18801517

27.Zelefsky, M.J., et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys, 2012. 83: 953.

https://www.ncbi.nlm.nih.gov/pubmed/22172904

28.Zamora-Ros, R., et al. Flavonoid and lignan intake in relation to bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Br J Cancer, 2014. 111: 1870.

https://www.ncbi.nlm.nih.gov/pubmed/25121955

29.Teleka, S., et al. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: A prospective pooled cohort study of 800,000 men and women. Int J Cancer, 2018. 143: 3071.

https://www.ncbi.nlm.nih.gov/pubmed/29756343

30.Xu, Y., et al. Diabetes mellitus and the risk of bladder cancer: A PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltimore), 2017. 96: e8588.

https://www.ncbi.nlm.nih.gov/pubmed/29145273

31.Adil, M., et al. Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic literature review and meta-analysis of observational studies using real-world data. Clinical Epidemiology and Global Health, 2018. 6: 61.

http://www.elsevier.com/journals/clinical-epidemiology-and-global-health/2213-3984

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexa&NEWS=N&AN=618029160

32.U.S. Food & Drug Adminstration. FDA Drug Safety Podcast 2016: Updated FDA review concludes that use of pioglitazone may be linked to an increased risk of bladder cancer. Access date December 2022.

https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-drug-safety-podcast-updated-fda-review-concludes-use-pioglitazone-may-be-linked-increased-risk

33.Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum, 1994. 61: 1.

https://www.ncbi.nlm.nih.gov/pubmed/7715068

34.Gouda, I., et al. Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Natl Canc Inst, 2007. 19: 158.

https://www.ncbi.nlm.nih.gov/pubmed/19034337

35.Salem, H.K., et al. Changing patterns (age, incidence, and pathologic types) of schistosoma-associated bladder cancer in Egypt in the past decade. Urology, 2012. 79: 379.

https://www.ncbi.nlm.nih.gov/pubmed/22112287

36.Pelucchi, C., et al. Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol, 2006. 3: 327.

https://www.ncbi.nlm.nih.gov/pubmed/16763645

37.Bayne, C.E., et al. Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis. World J Urol, 2018. 36: 1181.

https://www.ncbi.nlm.nih.gov/pubmed/29520590

38.Yu, Z., et al. The risk of bladder cancer in patients with urinary calculi: a meta-analysis. Urolithiasis, 2018. 46: 573.

https://www.ncbi.nlm.nih.gov/pubmed/29305631

39.Liu, S., et al. The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients. Int Urol Nephrol, 2015. 47: 951.

https://www.ncbi.nlm.nih.gov/pubmed/25894962

40.Waldhoer, T., et al. Sex Differences of >/= pT1 Bladder Cancer Survival in Austria: A Descriptive, Long-Term, Nation-Wide Analysis Based on 27,773 Patients. Urol Int, 2015. 94: 383.

https://www.ncbi.nlm.nih.gov/pubmed/25833466

41.Krimphove, M.J., et al. Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. Eur Urol Focus, 2021. 7: 124.

https://www.ncbi.nlm.nih.gov/pubmed/31227463

42.Patafio, F.M., et al. Is there a gender effect in bladder cancer? A population-based study of practice and outcomes. Can Urol Assoc J, 2015. 9: 269.

https://www.ncbi.nlm.nih.gov/pubmed/26316913

43.Andreassen, B.K., et al. Bladder cancer survival: Women better off in the long run. Eur J Cancer, 2018. 95: 52.

https://www.ncbi.nlm.nih.gov/pubmed/29635144

44.Cohn, J.A., et al. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation. Cancer, 2014. 120: 555.

https://www.ncbi.nlm.nih.gov/pubmed/24496869

45.Dietrich, K., et al. Parity, early menopause and the incidence of bladder cancer in women: a case-control study and meta-analysis. Eur J Cancer, 2011. 47: 592.

https://www.ncbi.nlm.nih.gov/pubmed/21067913

46.Scosyrev, E., et al. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer, 2009. 115: 68.

https://www.ncbi.nlm.nih.gov/pubmed/19072984

47.Stenzl, A. Words of wisdom. Re: sex and racial differences in bladder cancer presentation and mortality in the US. Eur Urol, 2010. 57: 729.

https://www.ncbi.nlm.nih.gov/pubmed/20965044

48.Abufaraj, M., et al. The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nurses’ Health Study and Nurses’ Health Study II. Int J Epidemiol, 2020. 49: 599.

https://www.ncbi.nlm.nih.gov/pubmed/31965144

49.Martin, C., et al. Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 2018. 110: 527.

https://www.ncbi.nlm.nih.gov/pubmed/29228305

50.Murta-Nascimento, C., et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev, 2007. 16: 1595.

https://www.ncbi.nlm.nih.gov/pubmed/17684133

51.Figueroa, J.D., et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet, 2014. 23: 1387.

https://www.ncbi.nlm.nih.gov/pubmed/24163127

52.Rothman, N., et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet, 2010. 42: 978.

https://www.ncbi.nlm.nih.gov/pubmed/20972438

53.Kiemeney, L.A., et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet, 2008. 40: 1307.

https://www.ncbi.nlm.nih.gov/pubmed/18794855

54.Varma, M., et al. Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol, 2020. 33: 700.

https://www.ncbi.nlm.nih.gov/pubmed/31685965

55.Paner, G.P., et al. Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma. Am J Surg Pathol, 2007. 31: 1420.

https://www.ncbi.nlm.nih.gov/pubmed/17721199

56.Weiner, A.B., et al. Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study. Eur Urol Oncol, 2019. 2: 304.

https://www.ncbi.nlm.nih.gov/pubmed/31200845

57.Stenzl, A. Current concepts for urinary diversion in women. Eur Urol (EAU Update series 1), 2003: 91.

https://www.infona.pl/resource/bwmeta1.element.elsevier-76dc31cc-6155-35b6-9e7a-9d277d5e662a

58.Varinot, J., et al. Full analysis of the prostatic urethra at the time of radical cystoprostatectomy for bladder cancer: impact on final disease stage. Virchows Arch, 2009. 455: 449.

https://www.ncbi.nlm.nih.gov/pubmed/19841937

59.Hansel, D.E., et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol, 2013. 63: 321.

https://www.ncbi.nlm.nih.gov/pubmed/23088996

60.Herr, H.W. Pathologic evaluation of radical cystectomy specimens. Cancer, 2002. 95: 668.

https://www.ncbi.nlm.nih.gov/pubmed/12209761

61.Fajkovic, H., et al. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis. Eur Urol, 2013. 64: 837.

https://www.ncbi.nlm.nih.gov/pubmed/22877503

62.Fritsche, H.M., et al. Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma. Eur Urol, 2013. 63: 739.

https://www.ncbi.nlm.nih.gov/pubmed/23079053

63.Neuzillet, Y., et al. Positive surgical margins and their locations in specimens are adverse prognosis features after radical cystectomy in non-metastatic carcinoma invading bladder muscle: results from a nationwide case-control study. BJU Int, 2013. 111: 1253.

https://www.ncbi.nlm.nih.gov/pubmed/23331375

64.Baltaci, S., et al. Reliability of frozen section examination of obturator lymph nodes and impact on lymph node dissection borders during radical cystectomy: results of a prospective multicentre study by the Turkish Society of Urooncology. BJU Int, 2011. 107: 547.

https://www.ncbi.nlm.nih.gov/pubmed/20633004

65.Jimenez, R.E., et al. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol, 2000. 24: 980.

https://www.ncbi.nlm.nih.gov/pubmed/10895820

66.Veskimae, E., et al. What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. Eur Urol Oncol, 2019. 2: 625.

https://www.ncbi.nlm.nih.gov/pubmed/31601522

67.Sjodahl, G., et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res, 2012. 18: 3377.

https://www.ncbi.nlm.nih.gov/pubmed/22553347

68.Choi, W., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell, 2014. 25: 152.

https://www.ncbi.nlm.nih.gov/pubmed/24525232

69.Sauter, G., et al. Tumours of the urinary system: non-invasive urothelial neoplasias. WHO classification of tumors of the urinary system and male genital organs, Lyon, France., 2004.

https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Pathology-And-Genetics-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2004

70.Moch, H., et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol, 2016. 70: 93.

https://www.ncbi.nlm.nih.gov/pubmed/26935559

71.WHO Classification of Tumours Editorial Board. WHO Classification of Tumours - Urinary and Male Genital Tumours. IARC, Lyon, France, 2022.

https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Urinary-And-Male-Genital-Tumours-2022

72.Comperat, E., et al. What’s new in WHO fifth edition - urinary tract. Histopathology, 2022. 81: 439.

https://www.ncbi.nlm.nih.gov/pubmed/35942645

73.Willis, D.L., et al. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol, 2015. 193: 1129.

https://www.ncbi.nlm.nih.gov/pubmed/25254936

74.Comperat, E., et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology, 2010. 42: 650.

https://www.ncbi.nlm.nih.gov/pubmed/21080874

75.Kaimakliotis, H.Z., et al. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? Urol Oncol, 2014. 32: 833.

https://www.ncbi.nlm.nih.gov/pubmed/24954925

76.Beltran, A.L., et al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch, 2014. 465: 199.

https://www.ncbi.nlm.nih.gov/pubmed/24878757

77.Soave, A., et al. Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? Urol Oncol, 2015. 33: 21 e1.

https://www.ncbi.nlm.nih.gov/pubmed/25465301

78.Masson-Lecomte, A., et al. Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy. World J Urol, 2015. 33: 1087.

https://www.ncbi.nlm.nih.gov/pubmed/25179011

79.Seisen, T., et al. Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection. Curr Opin Urol, 2014. 24: 524.

https://www.ncbi.nlm.nih.gov/pubmed/25051021

80.Willis, D.L., et al. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol, 2014. 32: 826.

https://www.ncbi.nlm.nih.gov/pubmed/24931270

81.Horwich, A., et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committeesdagger. Ann Oncol, 2019. 30: 1697.

https://www.ncbi.nlm.nih.gov/pubmed/31740927

82.Witjes, J.A., et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort(dagger): Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol, 2020. 77: 223.

https://www.ncbi.nlm.nih.gov/pubmed/31753752

83.Brierley JD, G.M., Wittekind C, TNM classification of malignant tumors. UICC International Union Against Cancer. 8th edn. 2016, Oxford.

http://www.uicc.org/resources/tnm/publications-resources

84.Jensen, J.B., et al. Incidence of occult lymph-node metastasis missed by standard pathological examination in patients with bladder cancer undergoing radical cystectomy. Scand J Urol Nephrol, 2011. 45: 419.

https://www.ncbi.nlm.nih.gov/pubmed/21767245

85.Mariappan, P., et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int, 2012. 109: 1666.

https://www.ncbi.nlm.nih.gov/pubmed/22044434

86.Comperat, E., et al. Dataset for the reporting of carcinoma of the bladder-cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Virchows Arch, 2020. 476: 521.

https://www.ncbi.nlm.nih.gov/pubmed/31915958

87.Magers, M.J., et al. Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. J Clin Pathol, 2019. 72: 550.

https://www.ncbi.nlm.nih.gov/pubmed/31164444

88.Martini, A., et al. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Cancer, 2019. 125: 3155.

https://www.ncbi.nlm.nih.gov/pubmed/31150110

89.Fossa, S.D., et al. Clinical significance of the “palpable mass” in patients with muscle-infiltrating bladder cancer undergoing cystectomy after pre-operative radiotherapy. Br J Urol, 1991. 67: 54.

https://www.ncbi.nlm.nih.gov/pubmed/1993277

90.Wijkstrom, H., et al. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients. Br J Urol, 1998. 81: 686.

https://www.ncbi.nlm.nih.gov/pubmed/9634042

91.Ploeg, M., et al. Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. Urol Oncol, 2012. 30: 247.

https://www.ncbi.nlm.nih.gov/pubmed/20451418

92.Blick, C.G., et al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int, 2012. 110: 84.

https://www.ncbi.nlm.nih.gov/pubmed/22122739

93.Wong, V.K., et al. Imaging and Management of Bladder Cancer. Cancers (Basel), 2021. 13: 1396.

https://www.ncbi.nlm.nih.gov/pubmed/33808614

94.Lokeshwar, V.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology, 2005. 66: 35.

https://www.ncbi.nlm.nih.gov/pubmed/16399415

95.Raitanen, M.P., et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol, 2002. 41: 284.

https://www.ncbi.nlm.nih.gov/pubmed/12180229

96.van Rhijn, B.W., et al. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol, 2005. 47: 736.

https://www.ncbi.nlm.nih.gov/pubmed/15925067

97.Wojcik, E.M., et al., The Paris System for Reporting Urinary Cytology, ed. E.M. Wojcik, Kurtycz, D.F.I., Rosenthal, D,L. . 2022, Switzerland.

98.Mariappan, P., et al. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol, 2010. 57: 843.

https://www.ncbi.nlm.nih.gov/pubmed/19524354

99.Stenzl, A., et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol, 2010. 184: 1907.

https://www.ncbi.nlm.nih.gov/pubmed/20850152

100.Burger, M., et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol, 2013. 64: 846.

https://www.ncbi.nlm.nih.gov/pubmed/23602406

101.Mazzucchelli, R., et al. Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer. Urology, 2009. 74: 385.

https://www.ncbi.nlm.nih.gov/pubmed/19501882

102.Pettus, J.A., et al. Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol, 2008. 53: 370.

https://www.ncbi.nlm.nih.gov/pubmed/17689003

103.Matzkin, H., et al. Transitional cell carcinoma of the prostate. J Urol, 1991. 146: 1207.

https://www.ncbi.nlm.nih.gov/pubmed/1942262

104.Mungan, M.U., et al. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur Urol, 2005. 48: 760.

https://www.ncbi.nlm.nih.gov/pubmed/16005563

105.Kassouf, W., et al. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol, 2008. 180: 164.

https://www.ncbi.nlm.nih.gov/pubmed/18485384

106.Walsh, D.L., et al. Dilemmas in the treatment of urothelial cancers of the prostate. Urol Oncol, 2009. 27: 352.

https://www.ncbi.nlm.nih.gov/pubmed/18439852

107.Lebret, T., et al. Urethral recurrence of transitional cell carcinoma of the bladder. Predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatocystectomy. Eur Urol, 1998. 33: 170.

https://www.ncbi.nlm.nih.gov/pubmed/9519359

108.Donat, S.M., et al. The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J Urol, 2001. 165: 1580.

https://www.ncbi.nlm.nih.gov/pubmed/11342921

109.von Rundstedt, F.C., et al. Transurethral biopsy of the prostatic urethra is associated with final apical margin status at radical cystoprostatectomy. J Clin Urol, 2016. 9: 404.

https://www.ncbi.nlm.nih.gov/pubmed/27818773

110.Kates, M., et al. Accuracy of urethral frozen section during radical cystectomy for bladder cancer. Urol Oncol, 2016. 34: 532 e1.

https://www.ncbi.nlm.nih.gov/pubmed/27432433

111.Comperat, E.M., et al. Grading of Urothelial Carcinoma and The New “World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016”. Eur Urol Focus, 2019. 5: 457.

https://www.ncbi.nlm.nih.gov/pubmed/29366854

112.AJCC Cancer Staging Manual. 8th ed. 2017, Cham, Switzerland.

https://www.springer.com/gp/book/9783319406176

113.Amin, M.B., et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin, 2017. 67: 93.

https://www.ncbi.nlm.nih.gov/pubmed/28094848

114.Tan, W.S., et al. Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria? J Urol, 2018. 200: 973.

https://www.ncbi.nlm.nih.gov/pubmed/29702097

115.Mallampati, G.K., et al. MR imaging of the bladder. Magn Reson Imaging Clin N Am, 2004. 12: 545.

https://www.ncbi.nlm.nih.gov/pubmed/15271370

116.Rajesh, A., et al. Bladder cancer: evaluation of staging accuracy using dynamic MRI. Clin Radiol, 2011. 66: 1140.

https://www.ncbi.nlm.nih.gov/pubmed/21924408

117.Huang, L., et al. The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis. Radiology, 2018. 286: 502.

https://www.ncbi.nlm.nih.gov/pubmed/29206594

118.Cornelissen, S.W.E., et al. Diagnostic Accuracy of Multiparametric MRI for Local Staging of Bladder Cancer: A Systematic Review and Meta-Analysis. Urology, 2020. 145: 22.

https://www.ncbi.nlm.nih.gov/pubmed/32721515

119.Panebianco, V., et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol, 2018. 74: 294.

https://www.ncbi.nlm.nih.gov/pubmed/29755006

120.Del Giudice, F., et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol, 2020. 77: 101.

https://www.ncbi.nlm.nih.gov/pubmed/31699526

121.Metwally, M.I., et al. The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study. Eur Radiol, 2021. 31: 6949.

https://www.ncbi.nlm.nih.gov/pubmed/33606105

122.Arita, Y., et al. Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant Histology. Eur Urol Oncol, 2023. 6: 99.

https://www.ncbi.nlm.nih.gov/pubmed/35933266

123.Bicchetti, M., et al. A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study. Radiol Med, 2022. 127: 881.

https://www.ncbi.nlm.nih.gov/pubmed/35763251

124.Woo, S., et al. Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol, 2020. 3: 306.

https://www.ncbi.nlm.nih.gov/pubmed/32199915

125.Del Giudice, F., et al. Systematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-Observer Reliability: An Added Value for Muscle Invasive Bladder Cancer Detection. Cancers (Basel), 2020. 12.

https://www.ncbi.nlm.nih.gov/pubmed/33076505

126.Bryan, R.T., et al. Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. Eur Urol, 2021. 80: 12.

https://www.ncbi.nlm.nih.gov/pubmed/33653635

127.Panebianco, V., et al. Clinical application of bladder MRI and the Vesical Imaging-Reporting And Data System. Nat Rev Urol, 2023.

https://www.ncbi.nlm.nih.gov/pubmed/38036666

128.Thomsen, H.S., Stacul, F., Bellin, M-F., Bongartz, G., et al ESUR Guidelines on Contrast Agents 10.0. 2018. 2021.

https://www.esur.org/fileadmin/content/2019/ESUR_Guidelines_10.0_Final_Version.pdf

129.Watanabe, M., et al. Clinical validity of non-contrast-enhanced VI-RADS: prospective study using 3-T MRI with high-gradient magnetic field. Eur Radiol, 2022. 32: 7513.

https://www.ncbi.nlm.nih.gov/pubmed/35554648

130.Kim, B., et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology, 1994. 193: 239.

https://www.ncbi.nlm.nih.gov/pubmed/8090898

131.Paik, M.L., et al. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol, 2000. 163: 1693.

https://www.ncbi.nlm.nih.gov/pubmed/10799162

132.Cowan, N.C., et al. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int, 2007. 99: 1363.

https://www.ncbi.nlm.nih.gov/pubmed/17428251

133.Hurel, S., et al. Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. World J Urol, 2015. 33: 335.

https://www.ncbi.nlm.nih.gov/pubmed/24810657

134.Verhoest, G., et al. Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol, 2011. 29: 495.

https://www.ncbi.nlm.nih.gov/pubmed/21681525

135.Takahashi, N., et al. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol, 2010. 183: 1330.

https://www.ncbi.nlm.nih.gov/pubmed/20171676

136.Kim, J.K., et al. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology, 2004. 231: 725.

https://www.ncbi.nlm.nih.gov/pubmed/15118111

137.Yang, W.T., et al. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. AJR Am J Roentgenol, 2000. 175: 759.

https://www.ncbi.nlm.nih.gov/pubmed/10954463

138.Barentsz, J.O., et al. MR imaging of the male pelvis. Eur Radiol, 1999. 9: 1722.

https://www.ncbi.nlm.nih.gov/pubmed/10602944

139.Lonati, C., et al. Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology - Young Academic Urologists. Urol Oncol, 2022. 40: 195 e27.

https://www.ncbi.nlm.nih.gov/pubmed/35236621

140.Wu, S., et al. Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study. Lancet Oncol, 2023. 24: 360.

https://www.ncbi.nlm.nih.gov/pubmed/36893772

141.Vind-Kezunovic, S., et al. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Results from a High-volume Centre Including Long-term Follow-up. Eur Urol Focus, 2019. 5: 90.

https://www.ncbi.nlm.nih.gov/pubmed/28753817

142.Mertens, L.S., et al. Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy. Eur Urol, 2023. 83: 95.

https://www.ncbi.nlm.nih.gov/pubmed/36202686

143.Ha, H.K., et al. Diagnostic Accuracy of F-18 FDG PET/CT for Preoperative Lymph Node Staging in Newly Diagnosed Bladder Cancer Patients: A Systematic Review and Meta-Analysis. Oncology, 2018. 95: 31.

https://www.ncbi.nlm.nih.gov/pubmed/29847834

144.Einerhand, S.M.H., et al. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer. Curr Opin Urol, 2020. 30: 654.

https://www.ncbi.nlm.nih.gov/pubmed/32701719

145.Voskuilen, C.S., et al. Staging (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer. Eur Urol Oncol, 2022. 5: 366.

https://www.ncbi.nlm.nih.gov/pubmed/33583752

146.Marandino, L., et al. [18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. Urol Oncol, 2021. 39: 235 e15.

https://www.ncbi.nlm.nih.gov/pubmed/33071107

147.Girvin, F., et al. Pulmonary nodules: detection, assessment, and CAD. AJR Am J Roentgenol, 2008. 191: 1057.

https://www.ncbi.nlm.nih.gov/pubmed/18806142

148.Heidenreich, A., et al. Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int, 2010. 85: 1.

https://www.ncbi.nlm.nih.gov/pubmed/20693823

149.Furrer, M.A., et al. Routine Preoperative Bone Scintigraphy Has Limited Impact on the Management of Patients with Invasive Bladder Cancer. Eur Urol Focus, 2021. 7: 1052.

https://www.ncbi.nlm.nih.gov/pubmed/33060038

150.Papageorgiou, I., et al. Whole-body MRI: a powerful alternative to bone scan for bone marrow staging without radiation and gadolinium enhancer. Clin Transl Oncol, 2020. 22: 1321.

https://www.ncbi.nlm.nih.gov/pubmed/31858434

151.Yoshida, S., et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys, 2012. 83: e21.

https://www.ncbi.nlm.nih.gov/pubmed/22414281

152.Bandini, M., et al. The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. Eur Urol Oncol, 2021. 4: 829.

https://www.ncbi.nlm.nih.gov/pubmed/32605888

153.Hafeez, S., et al. Assessing Bladder Radiotherapy Response With Quantitative Diffusion-Weighted Magnetic Resonance Imaging Analysis. Clin Oncol (R Coll Radiol), 2022. 34: 630.

https://www.ncbi.nlm.nih.gov/pubmed/35534398

154.Ko, W.S., et al. Predictive Value of 18 F-FDG PET/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer. Clin Nucl Med, 2023. 48: 574.

https://www.ncbi.nlm.nih.gov/pubmed/36976654

155.Pecoraro, M., et al. Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report. Abdom Radiol (NY), 2022. 47: 763.

https://www.ncbi.nlm.nih.gov/pubmed/34919160

156.Kozikowski, M., et al. Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus, 2022. 8: 728.

https://www.ncbi.nlm.nih.gov/pubmed/34099417

157.Civelek, A.C., et al. Clinical value of (18)FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. Urol Oncol, 2021. 39: 787 e17.

https://www.ncbi.nlm.nih.gov/pubmed/34140245

158.Rietbergen, D.D.D., et al. Evaluation of the Hybrid Tracer Indocyanine Green- 99m Tc-Nanocolloid for Sentinel Node Biopsy in Bladder Cancer-A Prospective Pilot Study. Clin Nucl Med, 2022. 47: 774.

https://www.ncbi.nlm.nih.gov/pubmed/35713891

159.Game, X., et al. Radical cystectomy in patients older than 75 years: assessment of morbidity and mortality. Eur Urol, 2001. 39: 525.

https://www.ncbi.nlm.nih.gov/pubmed/11464032

160.Clark, P.E., et al. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer, 2005. 104: 36.

https://www.ncbi.nlm.nih.gov/pubmed/15912515

161.May, M., et al. Results from three municipal hospitals regarding radical cystectomy on elderly patients. Int Braz J Urol, 2007. 33: 764.

https://www.ncbi.nlm.nih.gov/pubmed/18199344

162.Ethun, C.G., et al. Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. CA Cancer J Clin, 2017. 67: 362.

https://www.ncbi.nlm.nih.gov/pubmed/28731537

163.Miller, D.C., et al. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol, 2003. 169: 105.

https://www.ncbi.nlm.nih.gov/pubmed/12478114

164.Haden, T.D., et al. Comparative Perioperative Outcomes in Septuagenarians and Octogenarians Undergoing Radical Cystectomy for Bladder Cancer-Do Outcomes Differ? Eur Urol Focus, 2018. 4: 895.

https://www.ncbi.nlm.nih.gov/pubmed/28865996

165.Brown, A.S., et al. National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making. J Am Geriatr Soc, 1988. 36: 342.

https://www.ncbi.nlm.nih.gov/pubmed/3280648

166.Mayr, R., et al. Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer. J Cachexia Sarcopenia Muscle, 2018. 9: 505.

https://www.ncbi.nlm.nih.gov/pubmed/29479839

167.Lyon, T.D., et al. Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer, 2019. 17: 216.

https://www.ncbi.nlm.nih.gov/pubmed/31060857

168.Lawrentschuk, N., et al. Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol, 2010. 57: 983.

https://www.ncbi.nlm.nih.gov/pubmed/20227172

169.Donahue, T.F., et al. Risk factors for the development of parastomal hernia after radical cystectomy. J Urol, 2014. 191: 1708.

https://www.ncbi.nlm.nih.gov/pubmed/24384155

170.Djaladat, H., et al. The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer. BJU Int, 2014. 113: 887.

https://www.ncbi.nlm.nih.gov/pubmed/23906037

171.Garg, T., et al. Preoperative serum albumin is associated with mortality and complications after radical cystectomy. BJU Int, 2014. 113: 918.

https://www.ncbi.nlm.nih.gov/pubmed/24053616

172.van Hattum, J.W., et al. The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis. Bladder Cancer, 2022. 8: 211.

http://www.iospress.nl/journal/bladder-cancer/

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed23&NEWS=N&AN=638216172

173.Rochon, P.A., et al. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. A prospective comparison of three comorbidity indices. Med Care, 1996. 34: 1093.

https://www.ncbi.nlm.nih.gov/pubmed/8911426

174.Williams, S.B., et al. Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. Eur Urol Oncol, 2018. 1: 91.

https://www.ncbi.nlm.nih.gov/pubmed/30345422

175.Zietman, A.L., et al. Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy. Ann Med, 2000. 32: 34.

https://www.ncbi.nlm.nih.gov/pubmed/10711576

176.Lughezzani, G., et al. A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. Cancer, 2011. 117: 103.

https://www.ncbi.nlm.nih.gov/pubmed/20803606

177.Froehner, M., et al. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol, 2009. 56: 443.

https://www.ncbi.nlm.nih.gov/pubmed/19481861

178.Korc-Grodzicki, B., et al. Prevention of post-operative delirium in older patients with cancer undergoing surgery. J Geriatr Oncol, 2015. 6: 60.

https://www.ncbi.nlm.nih.gov/pubmed/25454768

179.Soubeyran, P., et al. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PLoS One, 2014. 9: e115060.

https://www.ncbi.nlm.nih.gov/pubmed/25503576

180.Rockwood, K., et al. A global clinical measure of fitness and frailty in elderly people. CMAJ, 2005. 173: 489.

https://www.ncbi.nlm.nih.gov/pubmed/16129869

181.de Groot, V., et al. How to measure comorbidity. a critical review of available methods. J Clin Epidemiol, 2003. 56: 221.

https://www.ncbi.nlm.nih.gov/pubmed/12725876

182.Linn, B.S., et al. Cumulative illness rating scale. J Am Geriatr Soc, 1968. 16: 622.

https://www.ncbi.nlm.nih.gov/pubmed/5646906

183.Charlson, M.E., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis, 1987. 40: 373.

https://www.ncbi.nlm.nih.gov/pubmed/3558716

184.Litwin, M.S., et al. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer, 2007. 109: 1777.

https://www.ncbi.nlm.nih.gov/pubmed/17354226

185.Paleri, V., et al. Applicability of the adult comorbidity evaluation - 27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study. J Laryngol Otol, 2002. 116: 200.

https://www.ncbi.nlm.nih.gov/pubmed/11893262

186.Greenfield, S., et al. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care, 1993. 31: 141.

https://www.ncbi.nlm.nih.gov/pubmed/8433577

187.Kaplan, M.H., et al. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis, 1974. 27: 387.

https://www.ncbi.nlm.nih.gov/pubmed/4436428

188.Farhat, J.S., et al. Are the frail destined to fail? Frailty index as predictor of surgical morbidity and mortality in the elderly. J Trauma Acute Care Surg, 2012. 72: 1526.

https://www.ncbi.nlm.nih.gov/pubmed/22695416

189.Mayr, R., et al. Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder. BJU Int, 2012. 110: E222.

https://www.ncbi.nlm.nih.gov/pubmed/22314129

190.Morgan, T.M., et al. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol, 2011. 186: 829.

https://www.ncbi.nlm.nih.gov/pubmed/21788035

191.Abdollah, F., et al. Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study. Ann Surg Oncol, 2012. 19: 309.

https://www.ncbi.nlm.nih.gov/pubmed/21701925

192.Koppie, T.M., et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer, 2008. 112: 2384.

https://www.ncbi.nlm.nih.gov/pubmed/18404699

193.Bolenz, C., et al. Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival. BJU Int, 2010. 106: 1324.

https://www.ncbi.nlm.nih.gov/pubmed/20500510

194.Yoo, S., et al. Does radical cystectomy improve overall survival in octogenarians with muscle-invasive bladder cancer? Korean J Urol, 2011. 52: 446.

https://www.ncbi.nlm.nih.gov/pubmed/21860763

195.Mayr, R., et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol, 2012. 62: 662.

https://www.ncbi.nlm.nih.gov/pubmed/22534059

196.Hall, W.H., et al. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer, 2004. 4: 94.

https://www.ncbi.nlm.nih.gov/pubmed/15610554

197.Extermann, M., et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol, 1998. 16: 1582.

https://www.ncbi.nlm.nih.gov/pubmed/9552069

198.Blagden, S.P., et al. Performance status score: do patients and their oncologists agree? Br J Cancer, 2003. 89: 1022.

https://www.ncbi.nlm.nih.gov/pubmed/12966419

199.Logothetis, C.J., et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol, 1995. 13: 2272.

https://www.ncbi.nlm.nih.gov/pubmed/7666085

200.von der Maase, H., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 2000. 18: 3068.

https://www.ncbi.nlm.nih.gov/pubmed/11001674

201.Niegisch, G., et al. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). Eur Urol, 2011. 60: 1087.

https://www.ncbi.nlm.nih.gov/pubmed/21839579

202.Cohen, H.J., et al. A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med, 2002. 346: 905.

https://www.ncbi.nlm.nih.gov/pubmed/11907291

203.Balducci, L., et al. General guidelines for the management of older patients with cancer. Oncology (Williston Park), 2000. 14: 221.

https://www.ncbi.nlm.nih.gov/pubmed/11195414

204.Castagneto, B., et al. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology, 2004. 67: 27.

https://www.ncbi.nlm.nih.gov/pubmed/15459492

205.Dutta, R., et al. Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. Urol Oncol, 2016. 34: 531 e1.

https://www.ncbi.nlm.nih.gov/pubmed/27427223

206.Mathieu, R., et al. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol, 2016. 13: 471.

https://www.ncbi.nlm.nih.gov/pubmed/27431340

207.Kimura, S., et al. Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis. J Urol, 2019. 201: 46.

https://www.ncbi.nlm.nih.gov/pubmed/30077559

208.Svatek, R.S., et al. Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy. Urology, 2014. 84: 1147.

https://www.ncbi.nlm.nih.gov/pubmed/25174656

209.Donat, S.M., et al. Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. J Urol, 2001. 165: 1117.

https://www.ncbi.nlm.nih.gov/pubmed/11257650

210.Paner, G.P., et al. Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. Adv Anat Pathol, 2017. 24: 113.

https://www.ncbi.nlm.nih.gov/pubmed/28398951

211.Moschini, M., et al. Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. Bladder Cancer, 2017. 3: 161.

https://www.ncbi.nlm.nih.gov/pubmed/28824943

212.Wu, S., et al. Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies. Cell Physiol Biochem, 2018. 46: 1352.

https://www.ncbi.nlm.nih.gov/pubmed/29689562

213.Ojerholm, E., et al. Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer, 2017. 123: 794.

https://www.ncbi.nlm.nih.gov/pubmed/27787873

214.Ku, J.H., et al. Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis. BMC Cancer, 2015. 15: 447.

https://www.ncbi.nlm.nih.gov/pubmed/26027955

215.Lee, D., et al. Lymph node density vs. the American Joint Committee on Cancer TNM nodal staging system in node-positive bladder cancer in patients undergoing extended or super-extended pelvic lymphadenectomy. Urol Oncol, 2017. 35: 151 e1.

https://www.ncbi.nlm.nih.gov/pubmed/28139370

216.Oszwald, A., et al. Pathological reporting of cystectomy lymph nodes: a retrospective analysis of experience in Paris. World J Urol, 2021. 39: 4029.

https://www.ncbi.nlm.nih.gov/pubmed/33743060

217.Jensen, J.B., et al. Evaluation of different lymph node (LN) variables as prognostic markers in patients undergoing radical cystectomy and extended LN dissection to the level of the inferior mesenteric artery. BJU Int, 2012. 109: 388.

https://www.ncbi.nlm.nih.gov/pubmed/21851538

218.Bruins, H.M., et al. Critical evaluation of the American Joint Committee on Cancer TNM nodal staging system in patients with lymph node-positive disease after radical cystectomy. Eur Urol, 2012. 62: 671.

https://www.ncbi.nlm.nih.gov/pubmed/22575915

219.Robertson, A.G., et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2017. 171: 540.

https://www.ncbi.nlm.nih.gov/pubmed/28988769

220.Choi, W., et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol, 2014. 11: 400.

https://www.ncbi.nlm.nih.gov/pubmed/24960601

221.Kamoun, A., et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol, 2020. 77: 420.

https://www.ncbi.nlm.nih.gov/pubmed/31563503

222.Abudurexiti, M., et al. Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer. Front Oncol, 2019. 9: 856.

https://www.ncbi.nlm.nih.gov/pubmed/31552180

223.Morera, D.S., et al. Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA. J Urol, 2020. 203: 62.

https://www.ncbi.nlm.nih.gov/pubmed/31112107

224.Comperat, E., et al. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Adv Anat Pathol, 2021. 28: 196.

https://www.ncbi.nlm.nih.gov/pubmed/34128484

225.Pietzak, E.J., et al. Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. Eur Urol, 2019. 75: 231.

https://www.ncbi.nlm.nih.gov/pubmed/30290956

226.Motterle, G., et al. Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol Focus, 2020. 6: 642.

https://www.ncbi.nlm.nih.gov/pubmed/31708469

227.Shariat, S.F., et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol, 2010. 183: 1744.

https://www.ncbi.nlm.nih.gov/pubmed/20299037

228.Plimack, E.R., et al. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol, 2015. 68: 959.

https://www.ncbi.nlm.nih.gov/pubmed/26238431

229.Van Allen, E.M., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov, 2014. 4: 1140.

https://www.ncbi.nlm.nih.gov/pubmed/25096233

230.Magliocco, A.M., et al. Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy. JAMA Netw Open, 2022. 5: e2242378.

https://www.ncbi.nlm.nih.gov/pubmed/36383379

231.Efstathiou, J.A., et al. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. Eur Urol, 2019. 76: 59.

https://www.ncbi.nlm.nih.gov/pubmed/30712971

232.Kamran, S.C., et al. Genomic Determinants of Response to Trimodality Therapy for Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology*Biology*Physics, 2022. 114: S24.

https://www.sciencedirect.com/science/article/pii/S0360301622010963

233.Miyamoto, D.T., et al. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncol, 2018. 19: e683.

https://www.ncbi.nlm.nih.gov/pubmed/30507435

234.Loriot, Y., et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 2019. 381: 338.

https://www.ncbi.nlm.nih.gov/pubmed/31340094

235.Pal, S.K., et al. Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Cancer Discov, 2018. 8: 812.

https://www.ncbi.nlm.nih.gov/pubmed/29848605

236.Rosenberg, J.E., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, 2016. 387: 1909.

https://www.ncbi.nlm.nih.gov/pubmed/26952546

237.European Medicines Agency. EMA restricts use of Keytruda and Tecentriq in bladder cancer. Press release 2018. Date accessed December 2021.

https://www.ema.europa.eu/en/news/ema-restricts-use-keytruda-tecentriq-bladder-cancer

238.Kandoth, C., et al. Mutational landscape and significance across 12 major cancer types. Nature, 2013. 502: 333.

https://www.ncbi.nlm.nih.gov/pubmed/24132290

239.Sharma, P., et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol, 2016. 17: 1590.

https://www.ncbi.nlm.nih.gov/pubmed/27733243

240.Powles, T., et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med, 2019. 25: 1706.

https://www.ncbi.nlm.nih.gov/pubmed/31686036

241.Necchi, A., et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol, 2018. 36: 3353.

https://www.ncbi.nlm.nih.gov/pubmed/30343614

242.Mariathasan, S., et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature, 2018. 554: 544.

https://www.ncbi.nlm.nih.gov/pubmed/29443960

243.Wang, L., et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun, 2018. 9: 3503.

https://www.ncbi.nlm.nih.gov/pubmed/30158554

244.Powles, T., et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature, 2021. 595: 432.

https://www.ncbi.nlm.nih.gov/pubmed/34135506

245.ClinicalTrials/gov. A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011) NCT04660344. Date accessed December 2022.

https://clinicaltrials.gov/ct2/show/NCT04660344

246.Bellmunt, J., et al. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clin Cancer Res, 2022. 28: 2050.

https://www.ncbi.nlm.nih.gov/pubmed/35247908

247.Liu, C., et al. Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients. Br J Cancer, 2022. 127: 1718.

https://www.ncbi.nlm.nih.gov/pubmed/35999267

248.Stein, J.P., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol, 2001. 19: 666.

https://www.ncbi.nlm.nih.gov/pubmed/11157016

249.Stein, J.P., et al. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol, 2006. 24: 296.

https://www.ncbi.nlm.nih.gov/pubmed/16518661

250.Dalbagni, G., et al. Cystectomy for bladder cancer: a contemporary series. J Urol, 2001. 165: 1111.

https://www.ncbi.nlm.nih.gov/pubmed/11257649

251.David, K.A., et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol, 2007. 178: 451.

https://www.ncbi.nlm.nih.gov/pubmed/17561135

252.Porter, M.P., et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol, 2011. 29: 252.

https://www.ncbi.nlm.nih.gov/pubmed/19450992

253.Ravi, P., et al. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU Int, 2021. 128: 607.

https://www.ncbi.nlm.nih.gov/pubmed/33909949

254.Sanchez-Ortiz, R.F., et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol, 2003. 169: 110.

https://www.ncbi.nlm.nih.gov/pubmed/12478115

255.Stein, J.P. Contemporary concepts of radical cystectomy and the treatment of bladder cancer. J Urol, 2003. 169: 116.

https://www.ncbi.nlm.nih.gov/pubmed/12478116

256.Boeri, L., et al. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. Eur Urol Oncol, 2019. 2: 390.

https://www.ncbi.nlm.nih.gov/pubmed/31277775

257.Pfail, J.L., et al. Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database. Bladder Cancer, 2020. 6: 265.

https://content.iospress.com/articles/bladder-cancer/blc200303

258.Pfister, C., et al. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Eur Urol, 2021. 79: 214.

https://www.ncbi.nlm.nih.gov/pubmed/32868138

259.Arora, A., et al. Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy. World J Urol, 2022. 40: 1697.

https://www.ncbi.nlm.nih.gov/pubmed/35488914

260.Sherif, A., et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol, 2004. 45: 297.

https://www.ncbi.nlm.nih.gov/pubmed/15036674

261.Kimura, S., et al. Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer, 2020. 18: 78.

https://www.ncbi.nlm.nih.gov/pubmed/31889669

262.D’Andrea, D., et al. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol, 2020. 38: 639 e1.

https://www.ncbi.nlm.nih.gov/pubmed/32057595

263.Grossman, H.B., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med, 2003. 349: 859.

https://www.ncbi.nlm.nih.gov/pubmed/12944571

264.International Collaboration of, T., et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol, 2011. 29: 2171.

https://www.ncbi.nlm.nih.gov/pubmed/21502557

265.Sherif, A., et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2. Scand J Urol Nephrol, 2002. 36: 419.

https://www.ncbi.nlm.nih.gov/pubmed/12623505

266.Sengelov, L., et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol, 2002. 41: 447.

https://www.ncbi.nlm.nih.gov/pubmed/12442921

267.Shipley, W.U., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol, 1998. 16: 3576.

https://www.ncbi.nlm.nih.gov/pubmed/9817278

268.Advanced Bladder Cancer Meta-analysis, C. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet, 2003. 361: 1927.

https://www.ncbi.nlm.nih.gov/pubmed/12801735

269.Winquist, E., et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol, 2004. 171: 561.

https://www.ncbi.nlm.nih.gov/pubmed/14713760

270.Advanced Bladder Cancer Meta-analysis, C. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol, 2005. 48: 202.

https://www.ncbi.nlm.nih.gov/pubmed/15939524

271.Orsatti, M., et al. Alternating chemo-radiotherapy in bladder cancer: a conservative approach. Int J Radiat Oncol Biol Phys, 1995. 33: 173.

https://www.ncbi.nlm.nih.gov/pubmed/7642415

272.Abol-Enein H, E.-M.M., El-Baz M, et al. . Neo-adjuvant chemotherapy in the treatment of invasive transitional bladder cancer. A controlled prospective randomized study. . Br J Urol 1997. 79 174. [No abstract available].

273.Malmstrom, P.U., et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol, 1996. 155: 1903.

https://www.ncbi.nlm.nih.gov/pubmed/8618283

274.Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet, 1999. 354: 533.

https://www.ncbi.nlm.nih.gov/pubmed/10470696

275.Yin, M., et al. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist, 2016. 21: 708.

https://www.ncbi.nlm.nih.gov/pubmed/27053504

276.Galsky, M.D., et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer, 2015. 121: 2586.

https://www.ncbi.nlm.nih.gov/pubmed/25872978

277.Yuh, B.E., et al. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol, 2013. 189: 1682.

https://www.ncbi.nlm.nih.gov/pubmed/23123547

278.Lee, F.C., et al. Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Adv Urol, 2013. 2013: 317190.

https://www.ncbi.nlm.nih.gov/pubmed/24382958

279.Dash, A., et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer, 2008. 113: 2471.

https://www.ncbi.nlm.nih.gov/pubmed/18823036

280.Choueiri, T.K., et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol, 2014. 32: 1889.

https://www.ncbi.nlm.nih.gov/pubmed/24821883

281.Plimack, E.R., et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol, 2014. 32: 1895.

https://www.ncbi.nlm.nih.gov/pubmed/24821881

282.Peyton, C.C., et al. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Oncol, 2018. 4: 1535.

https://www.ncbi.nlm.nih.gov/pubmed/30178038

283.Pfister, C., et al. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol, 2022. 40: 2013.

https://www.ncbi.nlm.nih.gov/pubmed/35254888

284.Hemenway, G., et al. Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy. Eur Urol Oncol, 2023. 6: 431.

https://www.ncbi.nlm.nih.gov/pubmed/35792045

285.Anari, F., et al. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol, 2018. 1: 54.

https://www.ncbi.nlm.nih.gov/pubmed/30420974

286.Iyer, G., et al. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol, 2018. 36: 1949.

https://www.ncbi.nlm.nih.gov/pubmed/29742009

287.Osterman, C.K., et al. Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer. Oncologist, 2019. 24: 688.

https://www.ncbi.nlm.nih.gov/pubmed/30728277

288.Hussain, S.A., et al. Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Lancet Oncol, 2022. 23: 650.

https://www.ncbi.nlm.nih.gov/pubmed/35421369

289.D’Andrea, D., et al. The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. Eur Urol Open Sci, 2022. 41: 74.

https://www.ncbi.nlm.nih.gov/pubmed/35813257

290.Vetterlein, M.W., et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer, 2017. 123: 4346.

https://www.ncbi.nlm.nih.gov/pubmed/28743155

291.Chakiryan, N.H., et al. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol, 2021. 206: 924.

https://www.ncbi.nlm.nih.gov/pubmed/34032503

292.Letocha, H., et al. Positron emission tomography with L-methyl-11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the urinary bladder. Br J Urol, 1994. 74: 767.

https://www.ncbi.nlm.nih.gov/pubmed/7827849

293.Nishimura, K., et al. The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall. Int Urol Nephrol, 2009. 41: 869.

https://www.ncbi.nlm.nih.gov/pubmed/19396568

294.Barentsz, J.O., et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology, 1998. 207: 791.

https://www.ncbi.nlm.nih.gov/pubmed/9609906

295.Krajewski, K.M., et al. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer, 2012. 48: 1495.

https://www.ncbi.nlm.nih.gov/pubmed/22176867

296.Rosenblatt, R., et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol, 2012. 61: 1229.

https://www.ncbi.nlm.nih.gov/pubmed/22189383

297.Voskuilen, C.S., et al. Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. Am J Surg Pathol, 2019. 43: 1600.

https://www.ncbi.nlm.nih.gov/pubmed/31524642

298.Sjodahl, G., et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol, 2022. 81: 523.

https://www.ncbi.nlm.nih.gov/pubmed/34782206

299.Takata, R., et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res, 2005. 11: 2625.

https://www.ncbi.nlm.nih.gov/pubmed/15814643

300.Takata, R., et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci, 2007. 98: 113.

https://www.ncbi.nlm.nih.gov/pubmed/17116130

301.Miron, B., et al. Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol Oncol, 2020. 3: 544.

https://www.ncbi.nlm.nih.gov/pubmed/32165095

302.Szabados, B., et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol, 2022. 82: 212.

https://www.ncbi.nlm.nih.gov/pubmed/35577646

303.Basile, G., et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial. Clin Cancer Res, 2022. 28: 5107.

https://www.ncbi.nlm.nih.gov/pubmed/36190522

304.van Dijk, N., et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med, 2020. 26: 1839.

https://www.ncbi.nlm.nih.gov/pubmed/33046870

305.Gao, J., et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med, 2020. 26: 1845.

https://www.ncbi.nlm.nih.gov/pubmed/33046869

306.Rose, T.L., et al. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol, 2021. 39: 3140.

https://www.ncbi.nlm.nih.gov/pubmed/34428076

307.Funt, S.A., et al. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. J Clin Oncol, 2022. 40: 1312.

https://www.ncbi.nlm.nih.gov/pubmed/35089812

308.Cathomas, R., et al. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. J Clin Oncol, 2023. 41: 5131.

https://www.ncbi.nlm.nih.gov/pubmed/37590894

309.Zaghloul, M.S., et al. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial. JAMA Surg, 2018. 153: e174591.

https://www.ncbi.nlm.nih.gov/pubmed/29188298

310.Iwata, T., et al. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. Urol Oncol, 2019. 37: 659.

https://www.ncbi.nlm.nih.gov/pubmed/31255542

311.Fonteyne, V., et al. Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial. Eur Urol Focus, 2022. 8: 1238.

https://www.ncbi.nlm.nih.gov/pubmed/34893458

312.Ballas, L., et al. Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study. Clin Genitourin Cancer, 2017. 15: 711.

https://www.ncbi.nlm.nih.gov/pubmed/28558986

313.Slack, N.H., et al. Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol, 1977. 9: 393.

https://www.ncbi.nlm.nih.gov/pubmed/330958

314.Smith, J.A., Jr., et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. J Urol, 1997. 157: 805.

https://www.ncbi.nlm.nih.gov/pubmed/9072571

315.Ghoneim, M.A., et al. Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J Urol, 1985. 134: 266.

https://www.ncbi.nlm.nih.gov/pubmed/3894693

316.Anderstrom, C., et al. A prospective randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma. Eur Urol, 1983. 9: 142.

https://www.ncbi.nlm.nih.gov/pubmed/6861819

317.Blackard, C.E., et al. Results of a clinical trial of surgery and radiation in stages II and 3 carcinoma of the bladder. J Urol, 1972. 108: 875.

https://www.ncbi.nlm.nih.gov/pubmed/5082739

318.Vassantachart, A., et al. Feasibility and Outcomes of Orthotopic Ileal Neobladder Reconstruction Following Pelvic Irradiation. Urology, 2021. 148: 198.

https://www.ncbi.nlm.nih.gov/pubmed/32979377

319.Huncharek, M., et al. Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer Res, 1998. 18: 1931.

https://www.ncbi.nlm.nih.gov/pubmed/9677446

320.El-Monim, H.A., et al. A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer. Urol Oncol, 2013. 31: 359.

https://www.ncbi.nlm.nih.gov/pubmed/21353794

321.Bamias, A., et al. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur Urol, 2023. 84: 381.

https://www.ncbi.nlm.nih.gov/pubmed/37217391

322.Seisen, T., et al. Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol, 2016. 34: 3529.

https://www.ncbi.nlm.nih.gov/pubmed/27269944

323.Fischer-Valuck, B.W., et al. Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy. Eur Urol Oncol, 2022. 5: 246.

https://www.ncbi.nlm.nih.gov/pubmed/35249864

324.Lehmann, J., et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol, 2009. 55: 1293.

https://www.ncbi.nlm.nih.gov/pubmed/19058907

325.Palma, D.A., et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol, 2020. 38: 2830.

https://www.ncbi.nlm.nih.gov/pubmed/32484754

326.Aboudaram, A., et al. Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with No Progression and with No More than Five Residual Metastatic Lesions Following First-Line Systemic Therapy: A Retrospective Analysis. Cancers (Basel), 2023. 15: 1161.

https://www.ncbi.nlm.nih.gov/pubmed/36831503

327.Bertucci, A., et al. Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020. Cancers (Basel), 2023. 15: 2069.

https://www.ncbi.nlm.nih.gov/pubmed/37046728

328.Zlotta, A.R., et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol, 2023. 24: 669.

https://www.ncbi.nlm.nih.gov/pubmed/37187202

329.Russell, B., et al. A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. Eur Urol Oncol, 2020. 3: 239.

https://www.ncbi.nlm.nih.gov/pubmed/31668714

330.Fahmy, O., et al. Clinicopathological Features and Prognostic Value of Incidental Prostatic Adenocarcinoma in Radical Cystoprostatectomy Specimens: A Systematic Review and Meta-Analysis of 13,140 Patients. J Urol, 2017. 197: 385.

https://www.ncbi.nlm.nih.gov/pubmed/27569436

331.Mottet, N., et al, EAU-EANM-ESTRO-ESUR-ISUP-SIOG Prostate Cancer Guidelines, in EAU Guidelines 2023, E.G. Office, Editor. 2023, EAU Guidelines Office Arnhem, The Netherlands.

https://uroweb.org/guidelines/prostate-cancer

332.Hernandez, V., et al. Oncological and functional outcomes of sexual function-preserving cystectomy compared with standard radical cystectomy in men: A systematic review. Urol Oncol, 2017. 35: 539 e17.

https://www.ncbi.nlm.nih.gov/pubmed/28495555

333.Voigt, M., et al. Influence of Simple and Radical Cystectomy on Sexual Function and Pelvic Organ Prolapse in Female Patients: A Scoping Review of the Literature. Sex Med Rev, 2019. 7: 408.

https://www.ncbi.nlm.nih.gov/pubmed/31029621

334.Ali-El-Dein, B., et al. Preservation of the internal genital organs during radical cystectomy in selected women with bladder cancer: a report on 15 cases with long term follow-up. Eur J Surg Oncol, 2013. 39: 358.

https://www.ncbi.nlm.nih.gov/pubmed/23422323

335.Bree, K.K., et al. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol, 2021. 206: 577.

https://www.ncbi.nlm.nih.gov/pubmed/33872050

336.Temkin, S.M., et al. Ovarian Cancer Prevention in High-risk Women. Clin Obstet Gynecol, 2017. 60: 738.

https://www.ncbi.nlm.nih.gov/pubmed/28957949

337.Veskimae, E., et al. Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU Int, 2017. 120: 12.

https://www.ncbi.nlm.nih.gov/pubmed/28220653

338.Patel, S.H., et al. Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage. Clin Genitourin Cancer, 2022. 20: 60.

https://www.ncbi.nlm.nih.gov/pubmed/34896022

339.Gupta, N., et al. Practice Patterns Regarding Female Reproductive Organ-Sparing and Nerve-Sparing Radical Cystectomy Among Urologic Oncologists in the United States. Clin Genitourin Cancer, 2023. 21: e236.

https://www.ncbi.nlm.nih.gov/pubmed/36801170

340.Bai, S., et al. The Feasibility and Safety of Reproductive Organ Preserving Radical Cystectomy for Elderly Female Patients With Muscle-Invasive Bladder Cancer: A Retrospective Propensity Score-matched Study. Urology, 2019. 125: 138.

https://www.ncbi.nlm.nih.gov/pubmed/30445122

341.Simone, G., et al. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int J Urol, 2013. 20: 390.

https://www.ncbi.nlm.nih.gov/pubmed/22970939

342.Jensen, J.B., et al. Extended versus limited lymph node dissection in radical cystectomy: impact on recurrence pattern and survival. Int J Urol, 2012. 19: 39.

https://www.ncbi.nlm.nih.gov/pubmed/22050425

343.Zehnder, P., et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol, 2011. 186: 1261.

https://www.ncbi.nlm.nih.gov/pubmed/21849183

344.Wallmeroth, A., et al. Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): An autopsy study on 367 patients. Urol Int, 1999. 62: 69.

https://www.ncbi.nlm.nih.gov/pubmed/10461106

345.Davies, J.D., et al. Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study. Urology, 2013. 81: 358.

https://www.ncbi.nlm.nih.gov/pubmed/23374802

346.Jensen, J.B., et al. Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery. BJU Int, 2010. 106: 199.

https://www.ncbi.nlm.nih.gov/pubmed/20002670

347.Leissner, J., et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol, 2004. 171: 139.

https://www.ncbi.nlm.nih.gov/pubmed/14665862

348.Dorin, R.P., et al. Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. Eur Urol, 2011. 60: 946.

https://www.ncbi.nlm.nih.gov/pubmed/21802833

349.Bruins, H.M., et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur Urol, 2014. 66: 1065.

https://www.ncbi.nlm.nih.gov/pubmed/25074764

350.Rai, B.P., et al. Robotic versus open radical cystectomy for bladder cancer in adults. Cochrane Database Syst Rev, 2019. 4: CD011903.

https://www.ncbi.nlm.nih.gov/pubmed/31016718

351.Khan, M.S., et al. A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). Eur Urol, 2016. 69: 613.

https://www.ncbi.nlm.nih.gov/pubmed/26272237

352.Khetrapal, P., et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials. Eur Urol, 2023. 84: 393.

https://www.ncbi.nlm.nih.gov/pubmed/37169638

353.Mastroianni, R., et al. Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial. J Urol, 2022. 207: 982.

https://www.ncbi.nlm.nih.gov/pubmed/34986007

354.Maibom, S.L., et al. Open vs robot-assisted radical cystectomy (BORARC): a double-blinded, randomised feasibility study. BJU Int, 2022. 130: 102.

https://www.ncbi.nlm.nih.gov/pubmed/34657367

355.Catto, J.W.F., et al. Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial. JAMA, 2022. 327: 2092.

https://www.ncbi.nlm.nih.gov/pubmed/35569079

356.Faraj, K.S., et al. Robot Assisted Radical Cystectomy vs Open Radical Cystectomy: Over 10 years of the Mayo Clinic Experience. Urol Oncol, 2019. 37: 862.

https://www.ncbi.nlm.nih.gov/pubmed/31526651

357.Wei, L., et al. Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence Following Robot-Assisted Radical Cystectomy. J Urol, 2019. 201: 1105.

https://www.ncbi.nlm.nih.gov/pubmed/30730413

358.Wijburg, C.J., et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Bladder Cancer Patients: A Multicentre Comparative Effectiveness Study. Eur Urol, 2021. 79: 609.

https://www.ncbi.nlm.nih.gov/pubmed/33446375

359.Goh, A.C., et al. A Population-based Study of Ureteroenteric Strictures After Open and Robot-assisted Radical Cystectomy. Urology, 2020. 135: 57.

https://www.ncbi.nlm.nih.gov/pubmed/31618656

360.Magnusson, J., et al. Cumulative incidence of ureteroenteric strictures after radical cystectomy in a population-based Swedish cohort. Scand J Urol, 2021. 55: 361.

https://www.ncbi.nlm.nih.gov/pubmed/34313191

361.Hosseini, A., et al. Ureteric stricture rates and management after robot-assisted radical cystectomy: a single-centre observational study. Scand J Urol, 2018. 52: 244.

https://www.ncbi.nlm.nih.gov/pubmed/30103644

362.Amin, K.A., et al. Predictors of Benign Ureteroenteric Anastomotic Strictures After Radical Cystectomy and Urinary Diversion. Urology, 2020. 144: 225.

https://www.ncbi.nlm.nih.gov/pubmed/29964128

363.Faraj, K.S., et al. Effect of intracorporeal urinary diversion on the incidence of benign ureteroenteric stricture after cystectomy. Int J Urol, 2021. 28: 593.

https://www.ncbi.nlm.nih.gov/pubmed/33594730

364.Ahmadi, N., et al. Use of indocyanine green to minimise uretero-enteric strictures after robotic radical cystectomy. BJU Int, 2019. 124: 302.

https://www.ncbi.nlm.nih.gov/pubmed/30815976

365.Reesink, D.J., et al. Evaluation of Ureteroenteric Anastomotic Strictures after the Introduction of Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Results from a Large Tertiary Referral Center. J Urol, 2021. 205: 1119.

https://www.ncbi.nlm.nih.gov/pubmed/33249976

366.Yang, L.S., et al. A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. Surg Oncol, 2016. 25: 281.

https://www.ncbi.nlm.nih.gov/pubmed/27566035

367.Cerruto, M.A., et al. Health-Related Quality of Life after Radical Cystectomy for Bladder Cancer in Elderly Patients with Ileal Orthotopic Neobladder or Ileal Conduit: Results from a Multicentre Cross-Sectional Study Using Validated Questionnaires. Urol Int, 2018. 100: 346.

https://www.ncbi.nlm.nih.gov/pubmed/29514144

368.Korkes, F., et al. Bricker ileal conduit vs. Cutaneous ureterostomy after radical cystectomy for bladder cancer: a systematic review. Int Braz J Urol, 2022. 48: 18.

https://www.ncbi.nlm.nih.gov/pubmed/33861058

369.Deliveliotis, C., et al. Urinary diversion in high-risk elderly patients: modified cutaneous ureterostomy or ileal conduit? Urology, 2005. 66: 299.

https://www.ncbi.nlm.nih.gov/pubmed/16040096

370.Rezaee, M.E., et al. Ileal Conduit Versus Continent Urinary Diversion in Radical Cystectomy: A Retrospective Cohort Study of 30-day Complications, Readmissions, and Mortality. Urology, 2022. 170: 139.

https://www.ncbi.nlm.nih.gov/pubmed/36007686

371.Izquierdo, L., et al. Radical cystectomy and orthotopic bladder substitution: surgical tricks and management of complications. Minerva Urol Nefrol, 2013. 65: 225.

https://www.ncbi.nlm.nih.gov/pubmed/24091476

372.Abol-Enein, H., et al. Functional results of orthotopic ileal neobladder with serous-lined extramural ureteral reimplantation: experience with 450 patients. J Urol, 2001. 165: 1427.

https://www.ncbi.nlm.nih.gov/pubmed/11342891

373.Thoeny, H.C., et al. Is ileal orthotopic bladder substitution with an afferent tubular segment detrimental to the upper urinary tract in the long term? J Urol, 2002. 168: 2030.

https://www.ncbi.nlm.nih.gov/pubmed/12394702

374.Yossepowitch, O., et al. Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. J Urol, 2003. 169: 177.

https://www.ncbi.nlm.nih.gov/pubmed/12478130

375.Laukhtina, E., et al. Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. Urol Oncol, 2021. 39: 806.

https://www.ncbi.nlm.nih.gov/pubmed/34266740

376.Wiesner, C., et al. Continent cutaneous urinary diversion: long-term follow-up of more than 800 patients with ileocecal reservoirs. World J Urol, 2006. 24: 315.

https://www.ncbi.nlm.nih.gov/pubmed/16676186

377.Check, D.K., et al. Decision Regret Related to Urinary Diversion Choice among Patients Treated with Cystectomy. J Urol, 2020. 203: 159.

https://www.ncbi.nlm.nih.gov/pubmed/31441673

378.Roth, B., et al. Positive Pre-cystectomy Biopsies of the Prostatic Urethra or Bladder Neck Do Not Necessarily Preclude Orthotopic Bladder Substitution. J Urol, 2019. 201: 909.

https://www.ncbi.nlm.nih.gov/pubmed/30694935

379.Stein, J.P., et al. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. J Urol, 2007. 178: 756.

https://www.ncbi.nlm.nih.gov/pubmed/17631333

380.Gakis, G., et al. [Benefits and risks of orthotopic neobladder reconstruction in female patients]. Aktuelle Urol, 2011. 42: 109.

https://www.ncbi.nlm.nih.gov/pubmed/21437834

381.Lebret, T., et al. After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer? Eur Urol, 2002. 42: 344.

https://www.ncbi.nlm.nih.gov/pubmed/12361899

382.Nieder, A.M., et al. Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring. Urology, 2004. 64: 950.

https://www.ncbi.nlm.nih.gov/pubmed/15533484

383.Xing, W., et al. Comparison of Health-Related Quality of Life Between Ileal Conduit Diversion and Orthotopic Neobladder in Women: A Meta-Analysis. Front Oncol, 2022. 12: 862884.

https://www.ncbi.nlm.nih.gov/pubmed/35419290

384.Gershman, B., et al. Comparative impact of continent and incontinent urinary diversion on long-term renal function after radical cystectomy in patients with preoperative chronic kidney disease 2 and chronic kidney disease 3a. Int J Urol, 2015. 22: 651.

https://www.ncbi.nlm.nih.gov/pubmed/25881721

385.Molenaar, C.J.L., et al. Effect of Multimodal Prehabilitation on Reducing Postoperative Complications and Enhancing Functional Capacity Following Colorectal Cancer Surgery: The PREHAB Randomized Clinical Trial. JAMA Surg, 2023. 158: 572.

https://www.ncbi.nlm.nih.gov/pubmed/36988937

386.Williams, S.B., et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol, 2020. 78: 719.

https://www.ncbi.nlm.nih.gov/pubmed/32624275

387.Xu, W., et al. Postoperative Pain Management after Radical Cystectomy: Comparing Traditional versus Enhanced Recovery Protocol Pathway. J Urol, 2015. 194: 1209.

https://www.ncbi.nlm.nih.gov/pubmed/26021824

388.Chiang, H.A., et al. Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. Eur Urol Focus, 2020. 6: 74.

https://www.ncbi.nlm.nih.gov/pubmed/30228076

389.Tikkinen , K.A.O., Cartwright, R., Gould, M.K., Naspro, R., Novara, G., Sandset,P.M., Violette, P.D., Guyatt, G.H., EAU Guidelines Thromboprophylaxis in Urological Surgery, in EAU Guidelines 2017: Arnhem, The Netherlands.

https://uroweb.org/guideline/thromboprophylaxis/

390.Bochner, B.H., et al. Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. Eur Urol, 2015. 67: 1042.

https://www.ncbi.nlm.nih.gov/pubmed/25496767

391.Mossanen, M., et al. Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. BJU Int, 2019. 124: 40.

https://www.ncbi.nlm.nih.gov/pubmed/30499636

392.Demaegd, L., et al. Comparison of postoperative complications of ileal conduits versus orthotopic neobladders. Transl Androl Urol, 2020. 9: 2541.

https://www.ncbi.nlm.nih.gov/pubmed/33457228

393.Cicione, A., et al. Complications and quality of life of ileal conduit, orthotopic neobladder and ureterocutaneostomy: systematic review of reports using the Clavien-Dindo Classification. Minerva Urol Nefrol, 2020. 72: 408.

https://www.ncbi.nlm.nih.gov/pubmed/32734749

394.Haas, M., et al. The comprehensive complication index is associated with a significant increase in complication severity between 30 and 90 days after radical cystectomy for bladder cancer. Eur J Surg Oncol, 2021. 47: 1163.

https://www.ncbi.nlm.nih.gov/pubmed/33046281

395.Furrer, M.A., et al. The Comprehensive Complication Index CCI: A proposed modification to optimize short-term complication reporting after cystectomy and urinary diversion. Urol Oncol, 2019. 37: 291 e9.

https://www.ncbi.nlm.nih.gov/pubmed/30638668

396.Hu, M., et al. Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. Cancer, 2014. 120: 1409.

https://www.ncbi.nlm.nih.gov/pubmed/24477968

397.Parker, W.P., et al. Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients. Clin Genitourin Cancer, 2017.

https://www.ncbi.nlm.nih.gov/pubmed/28844793

398.Diamant, E., et al. Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer. Cancers, 2022. 14: 3797.

https://www.mdpi.com/2072-6694/14/15/3797

399.Nielsen, M.E., et al. Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base. BJU Int, 2014. 114: 46.

https://www.ncbi.nlm.nih.gov/pubmed/24219110

400.Sari Motlagh, R., et al. Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. Curr Opin Urol, 2020. 30: 701.

https://www.ncbi.nlm.nih.gov/pubmed/32732625

401.Schulz, G.B., et al. Surgical High-risk Patients With ASA >/= 3 Undergoing Radical Cystectomy: Morbidity, Mortality, and Predictors for Major Complications in a High-volume Tertiary Center. Clin Genitourin Cancer, 2018. 16: e1141.

https://www.ncbi.nlm.nih.gov/pubmed/30174234

402.Hossain, D., Madaan, S. . Use of Clavien-Dindo classification in urology part 1 – pelvic surgery. Urology News 2016. 20.

https://www.urologynews.uk.com/features/features/post/use-of-clavien-dindo-classification-in-urology-part-1-pelvic-surgery

403.Reesink, D.J., et al. Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands. World J Urol, 2022. 40: 1469.

https://www.ncbi.nlm.nih.gov/pubmed/35397692

404.Shabsigh, A., et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol, 2009. 55: 164.

https://www.ncbi.nlm.nih.gov/pubmed/18675501

405.Buchner, A., et al. Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage. Scand J Urol, 2017. 51: 130.

https://www.ncbi.nlm.nih.gov/pubmed/28332428

406.Hammond, J., et al. Rates of venous thromboembolism among patients with major surgery for cancer. Ann Surg Oncol, 2011. 18: 3240.

https://www.ncbi.nlm.nih.gov/pubmed/21584837

407.Antoni, S., et al. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol, 2017. 71: 96.

https://www.ncbi.nlm.nih.gov/pubmed/27370177

408.Fahmy, O., et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol, 2018. 36: 43.

https://www.ncbi.nlm.nih.gov/pubmed/29102254

409.Darwish, C., et al. Trends in Treatment Strategies and Comparison of Outcomes in Lymph Node Positive Bladder Cancer: An Analysis of the National Cancer Database. Urology, 2020. 146: 168.

https://www.ncbi.nlm.nih.gov/pubmed/32866509

410.Bruins, H.M., et al. The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline Panel. Eur Urol Oncol, 2020. 3: 131.

https://www.ncbi.nlm.nih.gov/pubmed/31866215

411.Richters, A., et al. Hospital volume is associated with postoperative mortality after radical cystectomy for treatment of bladder cancer. BJU Int, 2021. 128: 511.

https://www.ncbi.nlm.nih.gov/pubmed/33404154

412.Llorente, C., et al. Effect of hospital volume on 90-day mortality after radical cystectomy for bladder cancer in Spain. World J Urol, 2020. 38: 1221.

https://www.ncbi.nlm.nih.gov/pubmed/31302754

413.Maisch, P., et al. Outcomes of palliative cystectomy in patients with locally advanced pT4 bladder cancer. Urol Oncol, 2021. 39: 368 e11.

https://www.ncbi.nlm.nih.gov/pubmed/33431328

414.Pieretti, A., et al. Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy. J Urol, 2021. 206: 29.

https://www.ncbi.nlm.nih.gov/pubmed/33617327

415.Ghahestani, S.M., et al. Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review. Urol J, 2009. 6: 149.

https://www.ncbi.nlm.nih.gov/pubmed/19711266

416.Srinivasan, V., et al. A comparison of two radiotherapy regimens for the treatment of symptoms from advanced bladder cancer. Clin Oncol (R Coll Radiol), 1994. 6: 11.

https://www.ncbi.nlm.nih.gov/pubmed/7513538

417.Herr, H.W. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol, 1987. 138: 1162.

https://www.ncbi.nlm.nih.gov/pubmed/3669160

418.Herr, H.W. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol, 2001. 19: 89.

https://www.ncbi.nlm.nih.gov/pubmed/11134199

419.Holmang, S., et al. Long-term followup of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. J Urol, 1997. 158: 389.

https://www.ncbi.nlm.nih.gov/pubmed/9224309

420.Solsona, E., et al. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol, 2010. 184: 475.

https://www.ncbi.nlm.nih.gov/pubmed/20620402

421.Choudhury, A., et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol, 2021. 22: 246.

https://www.ncbi.nlm.nih.gov/pubmed/33539743

422.Korpics, M., et al. Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: the impact of radiotherapy dose escalation. Journal of Radiation Oncology, 2017. 6: 387.

https://doi.org/10.1007/s13566-017-0319-2

423.Hafeez, S., et al. Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment. Int J Radiat Oncol Biol Phys, 2017. 98: 115.

https://www.ncbi.nlm.nih.gov/pubmed/28586948

424.Milosevic, M., et al. Radiotherapy for bladder cancer. Urology, 2007. 69: 80.

https://www.ncbi.nlm.nih.gov/pubmed/17280910

425.Sondergaard, J., et al. A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. Acta Oncol, 2014. 53: 1321.

https://www.ncbi.nlm.nih.gov/pubmed/24980045

426.Tonoli, S., et al. Radical radiotherapy for bladder cancer: retrospective analysis of a series of 459 patients treated in an Italian institution. Clin Oncol (R Coll Radiol), 2006. 18: 52.

https://www.ncbi.nlm.nih.gov/pubmed/16477920

427.Shelley, M.D., et al. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev, 2002: CD002079.

https://www.ncbi.nlm.nih.gov/pubmed/11869621

428.Booth, C.M., et al. Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study. Clin Oncol (R Coll Radiol), 2014. 26: 506.

https://www.ncbi.nlm.nih.gov/pubmed/24954284

429.Korpics, M.C., et al. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy. Cancer, 2017. 123: 3524.

https://www.ncbi.nlm.nih.gov/pubmed/28581675

430.Duchesne, G.M., et al. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys, 2000. 47: 379.

https://www.ncbi.nlm.nih.gov/pubmed/10802363

431.McLaren, D.B., et al. Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly. Radiother Oncol, 1997. 43: 171.

https://www.ncbi.nlm.nih.gov/pubmed/9192963

432.Galsky, M.D., et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol, 2011. 12: 211.

https://www.ncbi.nlm.nih.gov/pubmed/21376284

433.Galsky, M.D., et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol, 2011. 29: 2432.

https://www.ncbi.nlm.nih.gov/pubmed/21555688

434.Sternberg, C.N., et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer, 2003. 97: 1644.

https://www.ncbi.nlm.nih.gov/pubmed/12655521

435.Kachnic, L.A., et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol, 1997. 15: 1022.

https://www.ncbi.nlm.nih.gov/pubmed/9060542

436.Als, A.B., et al. Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies. Eur Urol, 2007. 52: 478.

https://www.ncbi.nlm.nih.gov/pubmed/17383078

437.Moran, G.W., et al. Systematic Review and Meta-Analysis on the Efficacy of Chemotherapy with Transurethral Resection of Bladder Tumors as Definitive Therapy for Muscle Invasive Bladder Cancer. Bladder Cancer, 2017. 3: 245.

https://www.ncbi.nlm.nih.gov/pubmed/29152549

438.Audenet, F., et al. Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data. J Urol, 2018. 200: 996.

https://www.ncbi.nlm.nih.gov/pubmed/29879397

439.Ploussard, G., et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol, 2014. 66: 120.

https://www.ncbi.nlm.nih.gov/pubmed/24613684

440.Giacalone, N.J., et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol, 2017. 71: 952.

https://www.ncbi.nlm.nih.gov/pubmed/28081860

441.Mak, R.H., et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol, 2014. 32: 3801.

https://www.ncbi.nlm.nih.gov/pubmed/25366678

442.Suer, E., et al. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy. World J Urol, 2016. 34: 847.

https://www.ncbi.nlm.nih.gov/pubmed/26462931

443.Efstathiou, J.A., et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol, 2012. 61: 705.

https://www.ncbi.nlm.nih.gov/pubmed/22101114

444.James, N.D., et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med, 2012. 366: 1477.

https://www.ncbi.nlm.nih.gov/pubmed/22512481

445.Amestoy, F., et al. Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. Crit Rev Oncol Hematol, 2019. 142: 76.

https://www.ncbi.nlm.nih.gov/pubmed/31377435

446.Hoskin, P.J., et al. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol, 2010. 28: 4912.

https://www.ncbi.nlm.nih.gov/pubmed/20956620

447.Coen, J.J., et al. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol, 2019. 37: 44.

https://www.ncbi.nlm.nih.gov/pubmed/30433852

448.de Haar-Holleman, A., et al. Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: A nationwide cohort study. Radiother Oncol, 2023. 183: 109584.

https://www.ncbi.nlm.nih.gov/pubmed/36863459

449.Kulkarni, G.S., et al. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol, 2017. 35: 2299.

https://www.ncbi.nlm.nih.gov/pubmed/28410011

450.Hall, E., et al. Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. Eur Urol, 2022. 82: 273.

https://www.ncbi.nlm.nih.gov/pubmed/35577644

451.Merten, R., et al. Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). Oncologist, 2019. 24: e1341.

https://www.ncbi.nlm.nih.gov/pubmed/31292267

452.Qiu, J., et al. Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis. J Oncol, 2022. 2022: 7306198.

https://www.ncbi.nlm.nih.gov/pubmed/35607328

453.Swinton, M., et al. Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer. J Clin Oncol, 2023. 41: 4406.

https://www.ncbi.nlm.nih.gov/pubmed/37478391

454.Krasnow, R.E., et al. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol, 2017. 72: 54.

https://www.ncbi.nlm.nih.gov/pubmed/28040351

455.Eswara, J.R., et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol, 2012. 187: 463.

https://www.ncbi.nlm.nih.gov/pubmed/22177159

456.Mitin, T., et al. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. Int J Radiat Oncol Biol Phys, 2016. 94: 67.

https://www.ncbi.nlm.nih.gov/pubmed/26700703

457.Sanchez, A., et al. Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. J Urol, 2018. 199: 407.

https://www.ncbi.nlm.nih.gov/pubmed/28870862

458.Efstathiou, J.A., et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol, 2009. 27: 4055.

https://www.ncbi.nlm.nih.gov/pubmed/19636019

459.Huddart, R.A., et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy +/- Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol, 2020. 77: 260.

https://www.ncbi.nlm.nih.gov/pubmed/31843338

460.Mak, K.S., et al. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys, 2016. 96: 1028.

https://www.ncbi.nlm.nih.gov/pubmed/27727064

461.Sherry, A.D., et al. Intensity-Modulated Radiotherapy is Superior to Three-Dimensional Conformal Radiotherapy in the Trimodality Management of Muscle-Invasive Bladder Cancer with Daily Cone Beam Computed Tomography Optimization. J Radiat Oncol, 2019. 8: 395.

https://www.ncbi.nlm.nih.gov/pubmed/33343830

462.Quirt, J.S., et al. Patterns of Referral to Radiation Oncology among Patients with Bladder Cancer: a Population-based Study. Clin Oncol (R Coll Radiol), 2017. 29: 171.

https://www.ncbi.nlm.nih.gov/pubmed/27829531

463.Donat, S.M., et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol, 2009. 55: 177.

https://www.ncbi.nlm.nih.gov/pubmed/18640770

464.Sylvester, R., et al. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol, 2000. 11: 851.

https://www.ncbi.nlm.nih.gov/pubmed/10997813

465.Advanced Bladder Cancer Meta-analysis, C. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol, 2005. 48: 189.

https://www.ncbi.nlm.nih.gov/pubmed/15939530

466.Leow, J.J., et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol, 2014. 66: 42.

https://www.ncbi.nlm.nih.gov/pubmed/24018020

467.Cognetti, F., et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol, 2012. 23: 695.

https://www.ncbi.nlm.nih.gov/pubmed/21859900

468.Paz-Ares, L.G., et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol (Meeting Abstracts), 2010. 28: LBA4518

http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA4518

469.Stadler, W.M., et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol, 2011. 29: 3443.

https://www.ncbi.nlm.nih.gov/pubmed/21810677

470.Powles, T., et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2018. 391: 748.

https://www.ncbi.nlm.nih.gov/pubmed/29268948

471.Freiha, F., et al. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol, 1996. 155: 495.

https://www.ncbi.nlm.nih.gov/pubmed/8558644

472.Stockle, M., et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol, 1995. 153: 47.

https://www.ncbi.nlm.nih.gov/pubmed/7966789

473.Skinner, D.G., et al. Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer. Semin Urol, 1990. 8: 279.

https://www.ncbi.nlm.nih.gov/pubmed/2284533

474.Lehmann, J., et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol, 2005. 23: 4963.

https://www.ncbi.nlm.nih.gov/pubmed/15939920

475.Studer, U.E., et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol, 1994. 152: 81.

https://www.ncbi.nlm.nih.gov/pubmed/8201695

476.Advanced Bladder Cancer Meta-analysis Collaborators, G. Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. Eur Urol, 2022. 81: 50.

https://www.ncbi.nlm.nih.gov/pubmed/34802798

477.Svatek, R.S., et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res, 2010. 16: 4461.

https://www.ncbi.nlm.nih.gov/pubmed/20651056

478.Sternberg, C.N., et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol, 2015. 16: 76.

https://www.ncbi.nlm.nih.gov/pubmed/25498218

479.Galsky, M.D., et al. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. J Clin Oncol, 2016. 34: 825.

https://www.ncbi.nlm.nih.gov/pubmed/26786930

480.Berg, S., et al. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer, 2019. 125: 1449.

https://www.ncbi.nlm.nih.gov/pubmed/30620387

481.Bajorin, D.F., et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med, 2021. 384: 2102.

https://www.ncbi.nlm.nih.gov/pubmed/34077643

482.Galsky, M.D., et al. Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score. Eur Urol, 2023. 83: 432.

https://www.ncbi.nlm.nih.gov/pubmed/36868932

483.Witjes, J.A., et al. Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial. Eur Urol Oncol, 2022. 5: 553.

https://www.ncbi.nlm.nih.gov/pubmed/35288066

484.Bellmunt, J., et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 2021. 22: 525.

https://www.ncbi.nlm.nih.gov/pubmed/33721560

485.U.S. Food & Drug Adminstration. FDA approves nivolumab for adjuvant treatment of urothelial carcinoma. Access date December 2022.

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma

486.Hussain, S.A., et al. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett, 2012. 3: 855.

https://www.ncbi.nlm.nih.gov/pubmed/22741006

487.Powles T, e.a., EV-302/KEYNOTE-A39: Open-lab, randomized phase III study of enfortumab vedotin in combination with pembrolizumab vs chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma, in ESMO 2023. 2023.

https://oncologypro.esmo.org/meeting-resources/esmo-congress/ev-302-keynote-a39-open-label-randomized-phase-iii-study-of-enfortumab-vedotin-in-combination-with-pembrolizumab-ev-p-vs-chemotherapy-chemo-i

488.van der Heijden, M.S., et al. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med, 2023. 389: 1778.

https://www.ncbi.nlm.nih.gov/pubmed/37870949

489.Hussain, S.A., et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer, 2004. 91: 844.

https://www.ncbi.nlm.nih.gov/pubmed/15292922

490.Morales-Barrera, R., et al. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer, 2012. 48: 1816.

https://www.ncbi.nlm.nih.gov/pubmed/22595043

491.De Santis, M., et al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol, 2009. 27: 5634.

https://www.ncbi.nlm.nih.gov/pubmed/19786668

492.Hoimes, C.J., et al. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol, 2023. 41: 22.

https://www.ncbi.nlm.nih.gov/pubmed/36041086

493.O’Donnell, P.H., et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol, 2023. 41: 4107.

https://www.ncbi.nlm.nih.gov/pubmed/37369081

494.Bellmunt, J., et al. New therapeutic challenges in advanced bladder cancer. Semin Oncol, 2012. 39: 598.

https://www.ncbi.nlm.nih.gov/pubmed/23040256

495.von der Maase, H., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol, 2005. 23: 4602.

https://www.ncbi.nlm.nih.gov/pubmed/16034041

496.Sternberg, C.N., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol, 2001. 19: 2638.

https://www.ncbi.nlm.nih.gov/pubmed/11352955

497.Sternberg, C.N., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer, 2006. 42: 50.

https://www.ncbi.nlm.nih.gov/pubmed/16330205

498.Bellmunt, J., et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol, 2012. 30: 1107.

https://www.ncbi.nlm.nih.gov/pubmed/22370319

499.Rosenberg, J.E., et al. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). J Clin Oncol, 2021. 39: 2486.

https://www.ncbi.nlm.nih.gov/pubmed/33989025

500.Galsky, M.D., et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol, 2012. 23: 406.

https://www.ncbi.nlm.nih.gov/pubmed/21543626

501.Bamias, A., et al. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Ann Oncol, 2018. 29: 361.

https://www.ncbi.nlm.nih.gov/pubmed/29077785

502.Galsky, M.D., et al. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. J Clin Oncol, 2020. 38: 1797.

https://www.ncbi.nlm.nih.gov/pubmed/32271672

503.Powles, T., et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 2020. 383: 1218.

https://www.ncbi.nlm.nih.gov/pubmed/32945632

504.Grivas, P., et al. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma. Eur Urol, 2023. 83: 320.

https://www.ncbi.nlm.nih.gov/pubmed/35654659

505.Sternberg, C.N., et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer, 2001. 92: 2993.

https://www.ncbi.nlm.nih.gov/pubmed/11753976

506.Meluch, A.A., et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol, 2001. 19: 3018.

https://www.ncbi.nlm.nih.gov/pubmed/11408496

507.Calabro, F., et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer, 2009. 115: 2652.

https://www.ncbi.nlm.nih.gov/pubmed/19396817

508.De Santis, M., et al. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol, 2016. 27: 449.

https://www.ncbi.nlm.nih.gov/pubmed/26673352

509.Balar, A.V., et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol, 2017. 18: 1483.

https://www.ncbi.nlm.nih.gov/pubmed/28967485

510.Balar, A.V., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, 2017. 389: 67.

https://www.ncbi.nlm.nih.gov/pubmed/27939400

511.Balar, A.V., et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol, 2023. 34: 289.

https://www.ncbi.nlm.nih.gov/pubmed/36494006

512.Iacovelli, R., et al. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. Ann Oncol, 2022. 33: 1179.

https://www.ncbi.nlm.nih.gov/pubmed/35926813

513.Rosenberg, J.E., et al. Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). J Clin Oncol, 2023. 41: 43.

https://www.ncbi.nlm.nih.gov/pubmed/35737919

514.Galsky, M.D., et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 2020. 395: 1547.

https://www.ncbi.nlm.nih.gov/pubmed/32416780

515.Powles, T., et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol, 2021. 22: 931.

https://www.ncbi.nlm.nih.gov/pubmed/34051178

516.Powles, T., et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol, 2020. 21: 1574.

https://www.ncbi.nlm.nih.gov/pubmed/32971005

517.Wong, R.L., et al. Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. Oncologist, 2021. 26: 1026.

https://www.ncbi.nlm.nih.gov/pubmed/34355457

518.Oing, C., et al. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol, 2016. 195: 254.

https://www.ncbi.nlm.nih.gov/pubmed/26410730

519.Raggi, D., et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol, 2016. 27: 49.

https://www.ncbi.nlm.nih.gov/pubmed/26487582

520.Albers, P., et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol, 2011. 22: 288.

https://www.ncbi.nlm.nih.gov/pubmed/20682548

521.Fechner, G., et al. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract, 2006. 60: 27.

https://www.ncbi.nlm.nih.gov/pubmed/16409425

522.Bellmunt, J., et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol, 2009. 27: 4454.

https://www.ncbi.nlm.nih.gov/pubmed/19687335

523.Petrylak, D.P., et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, 2017. 390: 2266.

https://www.ncbi.nlm.nih.gov/pubmed/28916371

524.Petrylak, D.P., et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol, 2020. 21: 105.

https://www.ncbi.nlm.nih.gov/pubmed/31753727

525.Bellmunt, J., et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med, 2017. 376: 1015.

https://www.ncbi.nlm.nih.gov/pubmed/28212060

526.Powles, T., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014. 515: 558.

https://www.ncbi.nlm.nih.gov/pubmed/25428503

527.Sharma, P., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2017. 18: 312.

https://www.ncbi.nlm.nih.gov/pubmed/28131785

528.Grimm, M.O., et al. Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2023. 24: 347.

https://www.ncbi.nlm.nih.gov/pubmed/36868252

529.Postow, M.A., et al. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med, 2018. 378: 158.

https://www.ncbi.nlm.nih.gov/pubmed/29320654

530.Brahmer, J.R., et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2018. 36: 1714.

https://www.ncbi.nlm.nih.gov/pubmed/29442540

531.Maher, V.E., et al. Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. J Clin Oncol, 2019. 37: 2730.

https://www.ncbi.nlm.nih.gov/pubmed/31116675

532.Rosenberg, J.E., et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol, 2019. 37: 2592.

https://www.ncbi.nlm.nih.gov/pubmed/31356140

533.Chang, E., et al. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res, 2021. 27: 922.

https://www.ncbi.nlm.nih.gov/pubmed/32962979

534.European Medicines Agency. Padcev - enfortumab vedotin, 2021. Access date December 2022.

https://www.ema.europa.eu/en/medicines/human/summaries-opinion/padcev

535.Yu, E.Y., et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV1397645928201): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2021. 22: 872.

https://www.ncbi.nlm.nih.gov/pubmed/33991512

536.Powles, T., et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med, 2021. 384: 1125.

https://www.ncbi.nlm.nih.gov/pubmed/33577729

537.Tagawa, S.T., et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol, 2021. 39: 2474.

https://www.ncbi.nlm.nih.gov/pubmed/33929895

538.Robertson, A.G., et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2018. 174: 1033.

https://www.ncbi.nlm.nih.gov/pubmed/30096301

539.Siefker-Radtke, A.O., et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. Lancet Oncol, 2022. 23: 248.

https://www.ncbi.nlm.nih.gov/pubmed/35030333

540.Loriot, Y., et al. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 2023. 389: 1961.

https://www.ncbi.nlm.nih.gov/pubmed/37870920

541.Siefker-Radtke, A.O., et al. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann Oncol, 2024. 35: 107.

https://www.ncbi.nlm.nih.gov/pubmed/37871702

542.Sternberg, C.N., et al. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. J Clin Oncol, 2023. 41: 629.

https://www.ncbi.nlm.nih.gov/pubmed/36240478

543.Birtle, A., et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet, 2020. 395: 1268.

https://www.ncbi.nlm.nih.gov/pubmed/32145825

544.Coleman, R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev, 2001. 27: 165.

https://www.ncbi.nlm.nih.gov/pubmed/11417967

545.Rosiello, G., et al. Sex- and age-related differences in the distribution of bladder cancer metastases. Jpn J Clin Oncol, 2021. 51: 976.

https://www.ncbi.nlm.nih.gov/pubmed/33558890

546.Aapro, M., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol, 2008. 19: 420.

https://www.ncbi.nlm.nih.gov/pubmed/17906299

547.Zaghloul, M.S., et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol, 2010. 15: 382.

https://www.ncbi.nlm.nih.gov/pubmed/20354750

548.Henry, D.H., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol, 2011. 29: 1125.

https://www.ncbi.nlm.nih.gov/pubmed/21343556

549.Rosen, L.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer, 2004. 100: 2613.

https://www.ncbi.nlm.nih.gov/pubmed/15197804

550.Smith, A.B., et al. Impact of bladder cancer on health-related quality of life. BJU Int, 2018. 121: 549.

https://www.ncbi.nlm.nih.gov/pubmed/28990272

551.Smith, A.B., et al. Quality of Life and Health State Utilities in Bladder Cancer. Bladder Cancer, 2022. 8: 55.

https://content.iospress.com/articles/bladder-cancer/blc211615

552.Cella, D.F., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol, 1993. 11: 570.

https://www.ncbi.nlm.nih.gov/pubmed/8445433

553.Aaronson, N.K., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 1993. 85: 365.

https://www.ncbi.nlm.nih.gov/pubmed/8433390

554.Ware, J.E., Jr., et al. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care, 1992. 30: 473.

https://www.ncbi.nlm.nih.gov/pubmed/1593914

555.Gilbert, S.M., et al. Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J Urol, 2010. 183: 1764.

https://www.ncbi.nlm.nih.gov/pubmed/20299056

556.Bessa, A., et al. Unmet needs in sexual health in bladder cancer patients: a systematic review of the evidence. BMC Urol, 2020. 20: 64.

https://www.ncbi.nlm.nih.gov/pubmed/32493286

557.Westhofen, T., et al. Baseline Health-related Quality of Life Predicts Bladder Cancer-specific Survival Following Radical Cystectomy. Eur Urol Focus, 2022. 8: 1659.

https://www.ncbi.nlm.nih.gov/pubmed/35184991

558.Ayyash, O., et al. New Mental Health Diagnosis as a Prognostic Factor for Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer, 2023. 21: e1.

https://www.ncbi.nlm.nih.gov/pubmed/36446679

559.Kitamura, H., et al. Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study. Jpn J Clin Oncol, 2020. 50: 1464.

https://www.ncbi.nlm.nih.gov/pubmed/32699909

560.Cerruto, M.A., et al. Systematic review and meta-analysis of non RCT’s on health related quality of life after radical cystectomy using validated questionnaires: Better results with orthotopic neobladder versus ileal conduit. Eur J Surg Oncol, 2016. 42: 343.

https://www.ncbi.nlm.nih.gov/pubmed/26620844

561.Mastroianni, R., et al. Comparison of Patient-reported Health-related Quality of Life Between Open Radical Cystectomy and Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Interim Analysis of a Randomised Controlled Trial. Eur Urol Focus, 2022. 8: 465.

https://www.ncbi.nlm.nih.gov/pubmed/33712389

562.Becerra, M.F., et al. Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy. J Urol, 2020. 204: 450.

https://www.ncbi.nlm.nih.gov/pubmed/32271690

563.Clements, M.B., et al. Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. J Urol, 2023. 209: 901.

https://www.ncbi.nlm.nih.gov/pubmed/36724053

564.Fossa, S.D., et al. Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer. Eur Urol, 1989. 16: 335.

https://www.ncbi.nlm.nih.gov/pubmed/2476317

565.Nagele, U., et al. The rationale for radical cystectomy as primary therapy for T4 bladder cancer. World J Urol, 2007. 25: 401.

https://www.ncbi.nlm.nih.gov/pubmed/17525849

566.Fokdal, L., et al. Radical radiotherapy for urinary bladder cancer: treatment outcomes. Expert Rev Anticancer Ther, 2006. 6: 269.

https://www.ncbi.nlm.nih.gov/pubmed/16445379

567.Rodel, C., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol, 2002. 20: 3061.

https://www.ncbi.nlm.nih.gov/pubmed/12118019

568.Vaughn, D.J., et al. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. J Clin Oncol, 2018. 36: 1579.

https://www.ncbi.nlm.nih.gov/pubmed/29590008

569.McGregor, B., et al. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. Eur Urol, 2022. 81: 515.

https://www.ncbi.nlm.nih.gov/pubmed/35168844

570.Malkowicz, S.B., et al. Muscle-invasive urothelial carcinoma of the bladder. Urology, 2007. 69: 3.

https://www.ncbi.nlm.nih.gov/pubmed/17280906

571.Karakiewicz, P.I., et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol, 2006. 176: 1354.

https://www.ncbi.nlm.nih.gov/pubmed/16952631

572.Zaak, D., et al. Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int, 2010. 106: 342.

https://www.ncbi.nlm.nih.gov/pubmed/20002664

573.Giannarini, G., et al. Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol, 2010. 58: 486.

https://www.ncbi.nlm.nih.gov/pubmed/20541311

574.Volkmer, B.G., et al. Oncological followup after radical cystectomy for bladder cancer-is there any benefit? J Urol, 2009. 181: 1587.

https://www.ncbi.nlm.nih.gov/pubmed/19233433

575.Boorjian, S.A., et al. Detection of asymptomatic recurrence during routine oncological followup after radical cystectomy is associated with improved patient survival. J Urol, 2011. 186: 1796.

https://www.ncbi.nlm.nih.gov/pubmed/21944088

576.Soukup, V., et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol, 2012. 62: 290.

https://www.ncbi.nlm.nih.gov/pubmed/22609313

577.Huguet, J. Follow-up after radical cystectomy based on patterns of tumour recurrence and its risk factors. Actas Urol Esp, 2013. 37: 376.

https://www.ncbi.nlm.nih.gov/pubmed/23611464

578.Ghoneim, M.A., et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol, 2008. 180: 121.

https://www.ncbi.nlm.nih.gov/pubmed/18485392

579.Donat, S.M. Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective? World J Urol, 2006. 24: 557.

https://www.ncbi.nlm.nih.gov/pubmed/17009050

580.Mathers, M.J., et al. Is there evidence for a multidisciplinary follow-up after urological cancer? An evaluation of subsequent cancers. World J Urol, 2008. 26: 251.

https://www.ncbi.nlm.nih.gov/pubmed/18421461

581.Vrooman, O.P., et al. Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice. Curr Opin Urol, 2010. 20: 437.

https://www.ncbi.nlm.nih.gov/pubmed/20657286

582.Cagiannos, I., et al. Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J, 2009. 3: S237.

https://www.ncbi.nlm.nih.gov/pubmed/20019993

583.Bekku, K., et al. Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma? Int J Clin Oncol, 2013. 18: 110.

https://www.ncbi.nlm.nih.gov/pubmed/22095246

584.Fahmy, O., et al. Urethral recurrence after radical cystectomy for urothelial carcinoma: A systematic review and meta-analysis. Urol Oncol, 2018. 36: 54.

https://www.ncbi.nlm.nih.gov/pubmed/29196179

585.Varol, C., et al. Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. J Urol, 2004. 172: 937.

https://www.ncbi.nlm.nih.gov/pubmed/15311003

586.Gakis, G., et al. Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. Eur Urol, 2017. 71: 545.

https://www.ncbi.nlm.nih.gov/pubmed/27720534

587.Picozzi, S., et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol, 2012. 188: 2046.

https://www.ncbi.nlm.nih.gov/pubmed/23083867

588.Sanderson, K.M., et al. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol, 2007. 177: 2088.

https://www.ncbi.nlm.nih.gov/pubmed/17509294

589.Stewart-Merrill, S.B., et al. Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach. Urol Oncol, 2015. 33: 339 e1.

https://www.ncbi.nlm.nih.gov/pubmed/26031371

590.Martini, A., et al. Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. J Urol, 2021. 206: 885.

https://www.ncbi.nlm.nih.gov/pubmed/34032498

591.Gupta, A., et al. Risk of fracture after radical cystectomy and urinary diversion for bladder cancer. J Clin Oncol, 2014. 32: 3291.

https://www.ncbi.nlm.nih.gov/pubmed/25185104

592.Madersbacher, S., et al. Long-term outcome of ileal conduit diversion. J Urol, 2003. 169: 985.

https://www.ncbi.nlm.nih.gov/pubmed/12576827

593.Shah, S.H., et al. Ureteroenteric Strictures After Open Radical Cystectomy and Urinary Diversion: The University of Southern California Experience. Urology, 2015. 86: 87.

https://www.ncbi.nlm.nih.gov/pubmed/25987494

594.Nieuwenhuijzen, J.A., et al. Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. Eur Urol, 2008. 53: 834.

https://www.ncbi.nlm.nih.gov/pubmed/17904276

595.Schmidt, B., et al. Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer. Eur Urol Open Sci, 2022. 35: 29.

https://www.ncbi.nlm.nih.gov/pubmed/35024629

596.Wood, D.N., et al. Stomal complications of ileal conduits are significantly higher when formed in women with intractable urinary incontinence. J Urol, 2004. 172: 2300.

https://www.ncbi.nlm.nih.gov/pubmed/15538253

597.Neal, D.E. Complications of ileal conduit diversion in adults with cancer followed up for at least five years. Br Med J (Clin Res Ed), 1985. 290: 1695.

https://www.ncbi.nlm.nih.gov/pubmed/3924218

598.Shimko, M.S., et al. Long-term complications of conduit urinary diversion. J Urol, 2011. 185: 562.

https://www.ncbi.nlm.nih.gov/pubmed/21168867

599.Clifford, T.G., et al. Prospective Evaluation of Continence Following Radical Cystectomy and Orthotopic Urinary Diversion Using a Validated Questionnaire. J Urol, 2016. 196: 1685.

https://www.ncbi.nlm.nih.gov/pubmed/27256205

600.Bartsch, G., et al. Urinary functional outcomes in female neobladder patients. World J Urol, 2014. 32: 221.

https://www.ncbi.nlm.nih.gov/pubmed/24317553

601.Stenzl, A., et al. Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors. Cancer, 2001. 92: 1864.

https://www.ncbi.nlm.nih.gov/pubmed/11745259

602.Hautmann, R.E., et al. Functional Outcome and Complications following Ileal Neobladder Reconstruction in Male Patients without Tumor Recurrence. More than 35 Years of Experience from a Single Center. J Urol, 2021. 205: 174.

https://www.ncbi.nlm.nih.gov/pubmed/32856988

603.Lenis, A.T., et al. Urinary Diversion. JAMA, 2020. 324: 2222.

https://pubmed.ncbi.nlm.nih.gov/33258891/